Manal M Hassan, MD, MPH, PhD

Peer-Reviewed Articles

1. Ohannesian N, Mallick MS, He J, Qiao Y, Li N, Shaitelman SF, Tang C, Shinn EH, Hofstetter WL, Goltsov A, Hassan MM, Hunt KK, Lin SH, Shih W. Plasmonic nano-aperture label-free imaging of single small extracellular vesicles for cancer detection. Communications Medicine 4(1), 2024. e-Pub 2024. PMID: 38796532.
2. Chamseddine S, Yavuz BG, Mohamed YI, Lee SS, Yao JC, Hu ZI, LaPelusa M, Xiao L, Sun R, Morris JS, Hatia RI, Hassan M, Duda DG, Diab M, Mohamed A, Nassar A, Amin HM, Kaseb AO. Circulating Galectin-3: A Prognostic Biomarker in Hepatocellular Carcinoma. Journal of Immunotherapy and Precision Oncology 7(4):255-262, 2024. e-Pub 2024. PMID: 39524465.
3. Mohamed YI, Lee SS, Demir T, Chamseddine S, Hu ZI, Xiao L, Elsayes K, Morris JS, Wolff RA, Hiatia R, Qayyum A, Rashid A, Duda DG, Yao JC, LaPelusa M, Koay EJ, Mahvash A, Azzam AA, Dumbrava EE, Hassan M, Amin HM, Kaseb AO. Circulating tumor DNA (ctDNA) as a biomarker of response to therapy in advanced Hepatocellular carcinoma treated with Nivolumab. Cancer Biomarkers 41(1):83-91, 2024. e-Pub 2024. PMID: 39269823.
4. Ni Z, Kundu P, McKean DF, Wheeler W, Albanes D, Andreotti G, Antwi SO, Arslan AA, Bamlet WR, Beane-Freeman LE, Berndt SI, Bracci PM, Brennan P, Buring JE, Chanock SJ, Gallinger S, Gaziano J, Giles GG, Giovannucci EL, Goggins MG, Goodman PJ, Haiman CA, Hassan MM, Holly EA, Hung RJ, Katzke V, Kooperberg C, Kraft P, LeMarchand L, Li D, McCullough ML, Milne RL, Moore SC, Neale RE, Oberg AL, Patel AV, Peters U, Rabe KG, Risch HA, Shu X, Smith-Byrne K, Visvanathan K, Wactawski-Wende J, White E, Wolpin BM, Yu H, Zeleniuch-Jacquotte A, Zheng W, Zhong J, Amundadottir LT, Stolzenberg-Solomon RZ, Klein AP. Genome-Wide Analysis to Assess if Heavy Alcohol Consumption Modifies the Association between SNPs and Pancreatic Cancer Risk. Cancer Epidemiology Biomarkers and Prevention 33(9):1229-1239, 2024. e-Pub 2024. PMID: 38869494.
5. Hassan, MM, Li, D, Han, Y, Byun, J, Hatia, RI, Long, E, Choi, J, Kelley, RK, Cleary, S, Lok, AS, Bracci, PM, Permuth, JB, Bucur, R, Yuan, JM, Singal, AG, Jalal, P, Ghobrial, RM, Santella, RM, Kono, Y, Shah, DJ, Nguyen, MH, Liu, G, Parikh, ND, Kim, RD, Wu, HC, El-Serag, H, Chang, P, Li, Y, Chun, YS, Lee, SS, Gu, J, Hawk, E, Sun, R, Huff, C, Rashid, A, Amin, H, Beretta, L, Wolff, RA, Antwi, SO, Patt, YZ, Hwang, LY, Klein, AP, Zhang, K, Schmidt, MA, White, DL, Goss, JA, Khaderi, SA, Marrero, JA, Cigarroa, FG, Shah, PK, Kaseb, A, Roberts, LR, Amos, CI. Genome-wide association study identifies high-impact susceptibility loci for HCC in North America. Hepatology 80(1):87-101, 2024. e-Pub 2024. PMID: 38381705.
6. Chamseddine S, LaPelusa M, Carter K, Nguyen V, Mohamed YI, Sakr Y, Rojas-Hernandez CM, Hatia RI, Hassan M, Goss JA, Elsayes KM, Rashid A, Sun R, Tran Cao HS, Amin HM, Kaseb AO. Severe febrile neutropenia and pancytopenia in a patient with advanced hepatocellular carcinoma treated with atezolizumab and bevacizumab: a case report, 2024. e-Pub 2024. PMID: 38989410.
7. Tran Cao HS, Witt RG, Elsayes KM, Baiomy AA, Xiao L, Palmquist S, Lee SS, Mohamed YI, Mahvash A, Tzeng CD, Chun YS, Koay EJ, Rashid A, Hassan MM, Yao JC, Vauthey J, Kaseb AO. Development of a Novel Comprehensive Hepatocellular Carcinoma Outcome Prognostic Scoring System With Integration of Imaging Features. Oncologist 29(6):e803-e810, 2024. e-Pub 2023. PMID: 38159256.
8. Chamseddine, SM, Lapelusa, M, Carter, K, Nguyen, V, Mohamed, YI, Sakr, Y, Rojas Hernandez, CM, Hatia, RI, Hassan, MM, Goss, JA, Elsayes, KM, Rashid, A, Sun, R, Cao, HT, Amin, H, Kaseb, A. Severe febrile neutropenia and pancytopenia in a patient with advanced hepatocellular carcinoma treated with atezolizumab and bevacizumab. Journal of Gastrointestinal Oncology 15(3):1324-1330, 2024. e-Pub 2024. PMID: 38989410.
9. Nikzad, N, Fuentes, DA, Roach, MA, Chowdhury, T, Cagley, MC, Badawy, M, Elkhesen, A, Hassan, MM, Elsayes, KM, Beretta, L, Koay, EJ, Jalal, P. Enhancement Pattern Mapping for Early Detection of Hepatocellular Carcinoma in Patients with Cirrhosis. Journal of Hepatocellular Carcinoma 11:595-606, 2024. e-Pub 2024. PMID: 38525156.
10. Balderrama-Brondani V, Griffin AM, Owen TJ, Merriman KW, Chahla BB, Varghese J, Jimenez C, Waguespack SG, Graham PH, Perrier ND, Fisher SB, Karam JA, Shah AY, Campbell M, Hassan MM, Habra MA. Incidence and Geographical Distribution of Adrenocortical Carcinoma: Retrospective Analysis of a State Cancer Registry. Endocrine Practice 30(1):25-30, 2024. e-Pub 2024. PMID: 37858722.
11. Chamseddine, SM, Lapelusa, M, Xiao, L, Mohamed, YI, Lee, SS, Hu, Z, Hatia, RI, Hassan, MM, Yao, JC, Duda, DG, Datar, S, Amin, H, Kaseb, A. Plasma Growth Hormone as a Prognostic Biomarker to Durvalumab and Tremelimumab in Patients with Advanced Hepatocellular Carcinoma. Journal of Hepatocellular Carcinoma 11:455-461, 2024. e-Pub 2024. PMID: 38463542.
12. Han Y, Byun J, Zhu C, Sun R, Roh JY, Cordell HJ, Lee HS, Shaw VR, Kang SW, Razjouyan J, Cooley MA, Hassan MM, Siminovitch KA, Folseraas T, Ellinghaus D, Bergquist A, Rushbrook SM, Franke A, Karlsen TH, Lazaridis KN, Study Group IP, McGlynn KA, Roberts LR, Amos CI. Multitrait genome-wide analyses identify new susceptibility loci and candidate drugs to primary sclerosing cholangitis. Nature communications 14(1):1069, 2023. e-Pub 2023. PMID: 36828809.
13. Moawad AW, Morshid A, Khalaf AM, Elmohr MM, Hazle JD, Fuentes D, Badawy M, Kaseb AO, Hassan M, Mahvash A, Szklaruk J, Qayyum A, Abusaif A, Bennett WC, Nolan TS, Camp B, Elsayes KM. Multimodality annotated hepatocellular carcinoma data set including pre- and post-TACE with imaging segmentation. Scientific Data 10(1):33, 2023. e-Pub 2023. PMID: 36653372.
14. Chamseddine S, Mohamed YI, Lee SS, Yao JC, Hu ZI, Tran Cao HS, Xiao L, Sun R, Morris JS, Hatia RI, Hassan M, Duda DG, Diab M, Mohamed A, Nassar A, Datar S, Amin HM, Kaseb AO. Clinical and Prognostic Biomarker Value of Blood-Circulating Inflammatory Cytokines in Hepatocellular Carcinoma. Oncology (Switzerland) 101(11):730-737, 2023. e-Pub 2023. PMID: 37467732.
15. Hatia RI, Eluri M, Hawk ET, Shalaby A, Karatas E, Shalaby A, Abdelhakeem A, Abdel-Wahab R, Chang P, Rashid A, Jalal PK, Amos CI, Han Y, Armaghany T, Shroff RT, Li D, Javle M, Hassan MM. Independent of Primary Sclerosing Cholangitis and Cirrhosis, Early Adulthood Obesity Is Associated with Cholangiocarcinoma. Cancer Epidemiology Biomarkers and Prevention 32(10):1338-1347, 2023. e-Pub 2023. PMID: 37540502.
16. King SD, Veliginti S, MCGJ B, Ren Z, Zheng W, Setiawan VW, Wilkens LR, Shu XO, Arslan AA, Beane Freeman LE, Bracci PM, Canzian F, Du M, Gallinger SJ, Giles GG, Goodman PJ, Haiman CA, Kogevinas M, Kooperberg C, LeMarchand L, Neale RE, Visvanathan K, White E, Albanes D, Andreotti G, Babic A, Berndt SI, Brais LK, Brennan P, Buring JE, Rabe KG, Bamlet WR, Chanock SJ, Fuchs CS, Gaziano JM, Giovannucci EL, Hackert T, Hassan MM, Katzke V, Kurtz RC, Lee IM, Malats N, Murphy N, Oberg AL, Orlow I, Porta M, Real FX, Rothman N, Sesso HD, Silverman DT, Thompson IM, Wactawski-Wende J, Wang X, Wentzensen N, Yu H, Zeleniuch-Jacquotte A, Yu K, Wolpin BM, Duell EJ, Li D, Hung RJ, Perdomo S, McCullough ML, Freedman ND, Patel AV, Peters U, Riboli E, Sund M, Tjønneland A, Zhong J, Van Den Eeden SK, Kraft P, Risch HA, Amundadottir LT, Klein AP, Stolzenberg-Solomon RZ, Antwi SO. Genetic Susceptibility to Nonalcoholic Fatty Liver Disease and Risk for Pancreatic Cancer: Mendelian Randomization. Cancer Epidemiology Biomarkers and Prevention 32(9):1265-1269, 2023. e-Pub 2023. PMID: 37351909.
17. Antwi SO, Heckman M, White L, Yan I, Sarangi V, Lauer KP, Reddy J, Ahmed F, Veliginti S, Mejías Febres ED, Hatia RI, Chang P, Izquierdo-Sanchez L, Boix L, Rojas A, Banales JM, Reig M, Stål P, Gómez MR, Singal AG, Li D, Hassan MM, Roberts LR, Patel T. Metabolic liver cancer. Human molecular genetics 32(16):2646-2655, 2023. e-Pub 2023. PMID: 37369012.
18. Antwi SO, Heckman M, White L, Yan I, Sarangi V, Lauer KP, Reddy J, Ahmed F, Veliginti S, Mejías Febres ED, Hatia RI, Chang P, Izquierdo-Sanchez L, Boix L, Rojas A, Banales JM, Reig M, Stål P, Gómez MR, Singal AG, Li D, Hassan MM, Roberts LR, Patel T. Metabolic liver cancer: associations of rare and common germline variants in one-carbon metabolism and DNA methylation genes, 2023. e-Pub 2023. PMID: 37369012.
19. Mohamed IB, Ismail MS, El Sabagh A, Afifi Abdelwahab AM, Polychronopoulou E, Kuo YF, Hassan M, Goss JA, Kanwal F, Jalal PK. Radiological-histopathological discordance in patients transplanted for HCC and its impact on post-transplant outcomes. Cancer medicine 12(14):15011-15025, 2023. e-Pub 2023. PMID: 37326440.
20. Hassa MM, Li D, Han Y, Byun J, Hatia RI, Long E, Choi J, et al. Genome-wide association identifies high-impact susceptibility loci for hepatocellular carcinoma in North America. Hepatology, 2023. e-Pub 2023.
21. Kaseb AO, Haque A, Vishwamitra D, Hassan MM, Xiao L, George B, Sahu V, Mohamed YI, Carmagnani Pestana R, Lombardo JL, Avritscher R, Yao JC, Wolff RA, Rashid A, Morris JS, Amin HM. Blockade of growth hormone receptor signaling by using pegvisomant. Frontiers in Oncology 12:986305, 2022. e-Pub 2022. PMID: 36276070.
22. Zheng J, Zhao L, Dong J, Chen H, Li D, Zhang X, Hassan MM, Steck SE, Li X, Xiang YB, Wang H. The role of dietary factors in nonalcoholic fatty liver disease to hepatocellular carcinoma progression. Clinical Nutrition 41(10):2295-2307, 2022. e-Pub 2022. PMID: 36096063.
23. Shiha G, Soliman R, Mikhail NNH, Carrat F, Azzi J, Nathalie GC, Toyoda H, Uojima H, Nozaki A, Takaguchi K, Hiraoka A, Atsukawa M, Abe H, Matsuura K, Mikami S, Watanabe T, Tsuji K, Ishikawa T, Suri V, Osinusi A, Ni L, Zou J, Sarin SK, Kumar M, Jalal PK, Hashim MA, Hassan M, Lopez SA, Bañares R, Ahumada AM, Mousa NH, Eslam M, Waked I. International multicenter validation of GES score for HCC risk stratification in chronic hepatitis C patients. Journal of Viral Hepatitis 29(9):807-816, 2022. e-Pub 2022. PMID: 35657138.
24. Li D, Zheng J, Hatia R, Hassan M, Daniel CR. Dietary Intake of Fatty Acids and Risk of Pancreatic Cancer. Journal of Nutrition 152(2):439-447, 2022. e-Pub 2022. PMID: 34665254.
25. Mohamed YI, Duda DG, Awiwi MO, Lee SS, Altameemi L, Xiao L, Morris JS, Wolff RA, Elsayes KM, Hatia RI, Qayyum A, Chamseddine SM, Rashid A, Yao JC, Mahvash A, Hassan MM, Amin HM, Kaseb AO. Plasma growth hormone is a potential biomarker of response to atezolizumab and bevacizumab in advanced hepatocellular carcinoma patients. Oncotarget 13(1):1314-1321, 2022. e-Pub 2022. PMID: 36473155.
26. Wang, Z, Baladandayuthapani, V, Kaseb, A, Amin, H, Hassan, MM, Wang, W, Morris, J. Bayesian Edge Regression in Undirected Graphical Models to Characterize Interpatient Heterogeneity in Cancer. Journal of the American Statistical Association 117(538):533-546, 2022. e-Pub 2022. PMID: 36090952.
27. Zheng J, Daniel CR, Hatia RI, Stuff J, Abdelhakeem AA, Rashid A, Chun YS, Jalal PK, Kaseb AO, Li D, Hassan MM. Dietary N-Nitroso Compounds and Risk of Hepatocellular Carcinoma. Hepatology 74(6):3161-3173, 2021. e-Pub 2021. PMID: 34233041.
28. Moussa I, Day RS, Li R, Kaseb A, Jalal PK, Daniel-MacDougall C, Hatia RI, Abdelhakeem A, Rashid A, Chun YS, Li D, Hassan MM. Association of dietary fat intake and hepatocellular carcinoma among US adults. Cancer medicine 10(20):7308-7319, 2021. e-Pub 2021. PMID: 34535983.
29. Julián-Serrano S, Yuan F, Wheeler W, Benyamin B, Machiela MJ, Arslan AA, Beane-Freeman LE, Bracci PM, Duell EJ, Du M, Gallinger S, Giles GG, Goodman PJ, Kooperberg C, Marchand LL, Neale RE, Shu XO, Van Den Eeden SK, Visvanathan K, Zheng W, Albanes D, Andreotti G, Ardanaz E, Babic A, Berndt SI, Brais LK, Brennan P, Bueno-de-Mesquita B, Buring JE, Chanock SJ, Childs EJ, Chung CC, Fabiánová E, Foretová L, Fuchs CS, Gaziano JM, Gentiluomo M, Giovannucci EL, Goggins MG, Hackert T, Hartge P, Hassan MM, Holcátová I, Holly EA, Hung RI, Janout V, Kurtz RC, Lee IM, Malats N, McKean D, Milne RL, Newton CC, Oberg AL, Perdomo S, Peters U, Porta M, Rothman N, Schulze MB, Sesso HD, Silverman DT, Thompson IM, Wactawski-Wende J, Weiderpass E, Wenstzensen N, White E, Wilkens LR, Yu H, Zeleniuch-Jacquotte A, Zhong J, Kraft P, Li D, Campbell PT, Petersen GM, Wolpin BM, Risch HA, Amundadottir LT, Klein AP, Yu K, Stolzenberg-Solomon RZ. Hepcidin-regulating iron metabolism genes and pancreatic ductal adenocarcinoma. American Journal of Clinical Nutrition 114(4):1408-1417, 2021. e-Pub 2021. PMID: 34258619.
30. Morris JS, Hassan MM, Zohner YE, Wang Z, Xiao L, Rashid A, Haque A, Abdel-Wahab R, Mohamed YI, Ballard KL, Wolff RA, George B, Li L, Allen G, Weylandt M, Li D, Wang W, Raghav K, Yao J, Amin HM, Kaseb AO. HepatoScore-14. Hepatology 73(6):2278-2292, 2021. e-Pub 2021. PMID: 32931023.
31. Moussa I, Day RS, Li R, Du XL, Kaseb AO, Jalal PK, Daniel-MacDougall C, Hatia RI, Abdelhakeem A, Rashid A, Chun YS, Li D, Hassan MM. Dietary Patterns and Hepatocellular Carcinoma Risk among US Adults. Nutrients 13(6), 2021. e-Pub 2021. PMID: 34208122.
32. Mocci E, Kundu P, Wheeler W, Arslan AA, Beane-Freeman LE, Bracci PM, Brennan P, Canzian F, Du M, Gallinger S, Giles GG, Goodman PJ, Kooperberg C, Le Marchand L, Neale RE, Shu XO, Visvanathan K, White E, Zheng W, Albanes D, Andreotti G, Babic A, Bamlet WR, Berndt SI, Blackford AL, Bueno-de-Mesquita B, Buring JE, Campa D, Chanock SJ, Childs EJ, Duell EJ, Fuchs CS, Gaziano JM, Giovannucci EL, Goggins MG, Hartge P, Hassan MM, Holly EA, Hoover RN, Hung RJ, Kurtz RC, Lee IM, Malats N, Milne RL, Ng K, Oberg AL, Panico S, Peters U, Porta M, Rabe KG, Riboli E, Rothman N, Scelo G, Sesso HD, Silverman DT, Stevens VL, Strobel O, Thompson IM, Tjonneland A, Trichopoulou A, Van Den Eeden SK, Wactawski-Wende J, Wentzensen N, Wilkens LR, Yu H, Yuan F, Zeleniuch-Jacquotte A, Amundadottir LT, Li D, Jacobs EJ, Petersen GM, Wolpin BM, Risch HA, Kraft P, Chatterjee N, Klein AP, Stolzenberg-Solomon R. Smoking modifies pancreatic cancer risk loci on 2q21.3. Cancer Research 81(11):3134-3143, 2021. e-Pub 2021. PMID: 33574088.
33. Mohamed YI, Lee S, Xiao L, Hassan MM, Qayyum A, Hiatia R, Pestana RC, Haque A, George B, Rashid A, Duda DG, Elghazaly H, Wolff RA, Morris JS, Yao J, Amin HM, Kaseb AO. Insulin-like growth factor 1/Child-Turcotte-Pugh composite score as a predictor of treatment outcomes in patients with advanced hepatocellular carcinoma treated with sorafenib. Oncotarget 12(8):756-766, 2021. e-Pub 2021. PMID: 33889299.
34. Ghoneim DH, Zhu J, Zheng W, Long J, Murff HJ, Ye F, Setiawan VW, Wilkens LR, Khankari NK, Haycock P, Antwi SO, Yang Y, Arslan AA, Beane Freeman LE, Bracci PM, Canzian F, Du M, Gallinger S, Giles GG, Goodman PJ, Kooperberg C, Le Marchand L, Neale RE, Scelo G, Visvanathan K, White E, Albanes D, Amiano P, Andreotti G, Babic A, Bamlet WR, Berndt SI, Brais LK, Brennan P, Bueno-de-Mesquita B, Buring JE, Campbell PT, Rabe KG, Chanock SJ, Duggal P, Fuchs CS, Gaziano JM, Goggins MG, Hackert T, Hassan MM, Helzlsouer KJ, Holly EA, Hoover RN, Katske V, Kurtz RC, Lee IM, Malats N, Milne RL, Murphy N, Oberg AL, Porta M, Rothman N, Sesso HD, Silverman DT, Thompson IM, Wactawski-Wende J, Wang X, Wentzensen N, Yu H, Zeleniuch-Jacquotte A, Yu K, Wolpin BM, Jacobs EJ, Duell EJ, Risch HA, Petersen GM, Amundadottir LT, Kraft P, Klein AP, Stolzenberg-Solomon RZ, Shu XO, Wu L. Mendelian Randomization Analysis of n-6 Polyunsaturated Fatty Acid Levels and Pancreatic Cancer Risk. Cancer Epidemiol Biomarkers Prev 29(12):2735-2739, 2020. e-Pub 2020. PMID: 32967863.
35. Abdel-Wahab R, Hassan MM, George B, Carmagnani Pestana R, Xiao L, Lacin S, Yalcin S, Shalaby AS, Al-Shamsi HO, Raghav K, Wolff RA, Yao JC, Girard L, Haque A, Duda DG, Dima S, Popescu I, Elghazaly HA, Vauthey JN, Aloia TA, Tzeng CW, Chun YS, Rashid A, Morris JS, Amin HM, Kaseb AO. Impact of Integrating Insulin-Like Growth Factor 1 Levels into Model for End-Stage Liver Disease Score for Survival Prediction in Hepatocellular Carcinoma Patients. Oncology:1-11. e-Pub 2020. PMID: 33027788.
36. Ismail MS, Hassan M, Khaderi SA, Yousry WA, Kamal El-Din MM, Bahaa El-Din MM, El Sayed OA, Kaseb AO, Goss JA, Kanwal F, Jalal PK. Clinical efficacy of direct-acting antiviral therapy for recurrent hepatitis C virus infection after liver transplantation in patients with hepatocellular carcinoma. World J Hepatol 12(9):628-640, 2020. e-Pub 2020. PMID: 33033569.
37. Yuan F, Hung RJ, Walsh N, Zhang H, Platz EA, Wheeler W, Song L, Arslan AA, Beane Freeman LE, Bracci P, Canzian F, Du M, Gallinger S, Giles GG, Goodman PJ, Kooperberg C, Le Marchand L, Neale RE, Rosendahl J, Scelo G, Shu XO, Visvanathan K, White E, Zheng W, Albanes D, Amiano P, Andreotti G, Babic A, Bamlet WR, Berndt SI, Brennan P, Bueno-de-Mesquita B, Buring JE, Campbell PT, Chanock SJ, Fuchs CS, Gaziano JM, Goggins MG, Hackert T, Hartge P, Hassan MM, Holly EA, Hoover RN, Katzke V, Kirsten H, Kurtz RC, Lee IM, Malats N, Milne RL, Murphy N, Ng K, Oberg AL, Porta M, Rabe KG, Real FX, Rothman N, Sesso HD, Silverman DT, Thompson IM, Wactawski-Wende J, Wang X, Wentzensen N, Wilkens LR, Yu H, Zeleniuch-Jacquotte A, Shi J, Duell EJ, Amundadottir LT, Li D, Petersen GM, Wolpin BM, Risch HA, Yu K, Klein AP, Stolzenberg-Solomon R. Genome-Wide Association Study Data Reveal Genetic Susceptibility to Chronic Inflammatory Intestinal Diseases and Pancreatic Ductal Adenocarcinoma Risk. Cancer Res 80(18):4004-4013, 2020. e-Pub 2020. PMID: 32641412.
38. Cristiano S, McKean D, Carey J, Bracci P, Brennan P, Chou M, Du M, Gallinger S, Goggins MG, Hassan MM, Hung RJ, Kurtz RC, Li D, Lu L, Neale R, Olson S, Petersen G, Rabe KG, Fu J, Risch H, Rosner GL, Ruczinski I, Klein AP, Scharpf RB. Bayesian copy number detection and association in large-scale studies. BMC Cancer 20(1):856, 2020. e-Pub 2020. PMID: 32894098.
39. Ismail MS, Hassan M, Martinez-Camacho A, May SB, Goss JA, Kanwal F, Jalal PK. Retrospective analysis of long-term outcome 10 years after liver transplantation for Wilson disease: experience over three decades. Transpl Int 33(8):925-935, 2020. e-Pub 2020. PMID: 32314442.
40. Turan A, Duncan A, Leung S, Karimi N, Fang J, Mao G, Hargrave J, Gillinov M, Trombetta C, Ayad S, Hassan M, Feider A, Howard-Quijano K, Ruetzler K, Sessler DI, Group DS. Dexmedetomidine for reduction of atrial fibrillation and delirium after cardiac surgery (DECADE): a randomised placebo-controlled trial. Lancet 396(10245):177-185, 2020. e-Pub 2020. PMID: 32682483.
41. Lacin S, Yalcin S, Karakas Y, Hassan MM, Amin H, Mohamed YI, Rashid A, Morris JS, Xiao L, Qayyum A, Kaseb AO. Prognostic Significance of Serum Insulin-Like Growth Factor-1 in Hepatocellular Cancer Patients: A Validation Study. J Hepatocell Carcinoma 7:143-153, 2020. e-Pub 2020. PMID: 32984091.
42. Qayyum A, Hwang KP, Stafford J, Verma A, Maru DM, Sandesh S, Sun J, Pestana RC, Avritscher R, Hassan MM, Amin H, Rashid A, Wistuba II, Ehman RL, Ma J, Kaseb AO. Immunotherapy response evaluation with magnetic resonance elastography (MRE) in advanced HCC. J Immunother Cancer 7(1):329, 2019. e-Pub 2019. PMID: 31779702.
43. Kaseb AO, Sánchez NS, Sen S, Kelley RK, Tan B, Bocobo AG, Lim KH, Abdel-Wahab R, Uemura M, Pestana RC, Qiao W, Xiao L, Morris J, Amin HM, Hassan MM, Rashid A, Banks KC, Lanman RB, Talasaz A, Mills-Shaw KR, George B, Haque A, Raghav KPS, Wolff RA, Yao JC, Meric-Bernstam F, Ikeda S, Kurzrock R. Molecular Profiling of Hepatocellular Carcinoma Using Circulating Cell-Free DNA. Clin Cancer Res 25(20):6107-6118, 2019. e-Pub 2019. PMID: 31363003.
44. Morshid A, Elsayes KM, Khalaf AM, Elmohr MM, Yu J, Kaseb AO, Hassan M, Mahvash A, Wang Z, Hazle JD, Fuentes D. A machine learning model to predict hepatocellular carcinoma response to transcatheter arterial chemoembolization. Radiol Artif Intell 1(5), 2019. e-Pub 2019. PMID: 31858078.
45. Li D, Tang H, Wei P, Zheng J, Daniel CR, Hassan MM. Vitamin C and Vitamin E Mitigate the Risk of Pancreatic Ductal Adenocarcinoma from Meat-Derived Mutagen Exposure in Adults in a Case-Control Study. J Nutr 149(8):1443-1450, 2019. e-Pub 2019. PMID: 31100111.
46. Habra MA, Sukkari MA, Hasan A, Albousen Y, Elsheshtawi MA, Jimenez C, Campbell M, Karam JA, Graham PH, Hatia RI, Phan AT, Varghese J, Hassan MM. Epidemiological risk factors for adrenocortical carcinoma: A hospital-based case-control study. Int J Cancer 146(7):1836-1840. e-Pub 2019. PMID: 31241762.
47. Chan LC, Li CW, Xia W, Hsu JM, Lee HH, Cha JH, Wang HL, Yang WH, Yen EY, Chang WC, Zha Z, Lim SO, Lai YJ, Liu C, Liu J, Dong Q, Yang Y, Sun L, Wei Y, Nie L, Hsu JL, Li H, Ye Q, Hassan MM, Amin HM, Kaseb AO, Lin X, Wang SC, Hung MC. IL-6/JAK1 pathway drives PD-L1 Y112 phosphorylation to promote cancer immune evasion. J Clin Invest 129(8):3324-3338, 2019. e-Pub 2019. PMID: 31305264.
48. Chen F, Childs EJ, Mocci E, Bracci P, Gallinger S, Li D, Neale RE, Olson SH, Scelo G, Bamlet WR, Blackford AL, Borges M, Brennan P, Chaffee KG, Duggal P, Hassan MJ, Holly EA, Hung RJ, Goggins MG, Kurtz RC, Oberg AL, Orlow I, Yu H, Petersen GM, Risch HA, Klein AP. Analysis of Heritability and Genetic Architecture of Pancreatic Cancer: A PanC4 Study. Cancer Epidemiol Biomarkers Prev 28(7):1238-1245, 2019. e-Pub 2019. PMID: 31015203.
49. Fuentes D, Ahmed K, Lin JS, Abdel-Wahab R, Kaseb AO, Hassan M, Szklaruk J, Morshid A, Hazle JD, Qayyum A, Elsayes KM. Automated Volumetric Assessment of Hepatocellular Carcinoma Response to Sorafenib: A Pilot Study. J Comput Assist Tomogr 43(3):499-506, 2019. e-Pub 2019. PMID: 31082956.
50. Zheng J, Stuff J, Tang H, Hassan MM, Daniel CR, Li D. Dietary N-nitroso compounds and risk of pancreatic cancer: results from a large case-control study. Carcinogenesis 10(2):1093, 2019. e-Pub 2019. PMID: 30475991.
51. Pestana RC, Hasssan MM, Abdel-Wahab R, Abugabal YI, Girard LM, Li D, Ping C, Raghav K, Morris J, Wolff RA, Rashid A, Amin HM, Kaseb KO. Clinical and prognostic significance of circulating levels of angiopoietin-1 and angiopoietin-2 in hepatocellular carcinoma. Oncotarget 9(102):37721-37732, 2018. e-Pub 2018. PMID: 30701027.
52. Mehrotra R, Tulsyan S, Hussain S, Mittal B, Singh Saluja S, Singh S, Tanwar P, Khan A, Javle M, Hassan MM, Pant S, de Aretxabala X, Sirohi B, Rajaraman P, Kaur T, Rath GK. Genetic landscape of gallbladder cancer: Global overview. Mutat Res 778:61-71, 2018. e-Pub 2018. PMID: 30454684.
53. Al Omari A, Abdelkhaleq H, Al-Hussaini M, Turfa R, Awad N, Hassan MM, Alfaqih MA, Garrett CR. Validation of the survival benefits of metformin in Jordanian patients with type II diabetes mellitus and colorectal cancer. J Glob Oncol 4(4):1-10, 2018. e-Pub 2018. PMID: 30084749.
54. Niekamp A, Abdel-Wahab R, Kuban J, Odisio BC, Mahvash A, Hassan MM, Qayyum A, Kaseb A, Sheth RA. Baseline Apparent Diffusion Coefficient as a Predictor of Response to Liver-Directed Therapies in Hepatocellular Carcinoma. J Clin Med 7(4):83, 2018. e-Pub 2018. PMID: 29661994.
55. Khalaf AM, Fuentes D, Morshid AI, Burke MR, Kaseb AO, Hassan M, Hazle JD, Elsayes KM. Role of Wnt/β-catenin signaling in hepatocellular carcinoma, pathogenesis, and clinical significance. J Hepatocell Carcinoma 57(5):61-73, 2018. e-Pub 2018. PMID: 29984212.
56. Dandachi D, Hassan M, Kaseb A, Angelidakis G, Torres HA. Hepatitis C virus-associated hepatocellular carcinoma as a second primary malignancy: exposing an overlooked presentation of liver cancer. J Hepatocell Carcinoma 2(5):81-86, 2018. e-Pub 2018. PMID: 30123783.
57. Hassan MM, Botrus G, Abdel-Wahab R, Wolff RA, Li D, Tweardy D, Phan AT, Hawk E, Javle M, Lee JS, Torres HA, Rashid A, Lenzi R, Hassabo HM, Abaza Y, Shalaby AS, Lacin S, Morris J, Patt YZ, Amos CI, Khaderi SA, Goss JA, Jalal PK, Kaseb AO. Estrogen Replacement Reduces Risk and Increases Survival Times of Women With Hepatocellular Carcinoma. Clin Gastroenterol Hepatol 15(11):1791-1799, 2017. e-Pub 2017. PMID: 28579181.
58. Takeuchi S, Rohren EM, Abdel-Wahab R, Xiao L, Morris JS, Macapinlac HA, Hassan MM, Kaseb AO. Refining prognosis in patients with hepatocellular carcinoma through incorporation of metabolic imaging biomarkers. Eur J Nucl Med Mol Imaging 44(6):969-978, 2017. e-Pub 2017. PMID: 27942837.
59. Pelucchi C, Rosato V, Bracci PM, Li D, Neale RE, Lucenteforte E, Serraino D, Anderson KE, Fontham E, Holly EA, Hassan MM, Polesel J, Bosetti C, Strayer L, Su J, Boffetta P, Duell EJ, La Vecchia C. Dietary acrylamide and the risk of pancreatic cancer in the International Pancreatic Cancer Case-Control Consortium (PANC4). Ann Oncol 28(2):408-414, 2017. e-Pub 2017. PMID: 27836886.
60. Al-Shamsi HO, Abdel-Wahab R, Hassan MM, Shalaby AS, Dahbour I, Lacin S, Mahvash A, Odisio BC, Murthy R, Avritscher R, Abdelsalam ME, Rashid A, Vauthey JN, Aloia TA, Conrad C, Chun YS, Krishnan S, Das P, Koay EJ, Amin HM, Yao JC, Kaseb AO. Natural History of T1N0M0 Hepatocellular Carcinoma: Large-Scale Study in the United States. Oncology 93(4):233-242, 2017. e-Pub 2017. PMID: 28683459.
61. Al-Shamsi HO, Jones J, Fahmawi Y, Dahbour I, Tabash A, Abdel-Wahab R, Abousamra AO, Shaw KR, Xiao L, Hassan MM, Kipp BR, Kopetz S, Soliman AS, McWilliams RR, Wolff RA. Molecular spectrum ofKRAS,NRAS,BRAF,PIK3CA,TP53, andAPCsomatic gene mutations in Arab patients with colorectal cancer: determination of frequency and distribution pattern. J Gastrointest Oncol 7(6):882-902, 2016. e-Pub 2016. PMID: 28078112.
62. Liu C, Eng C, Shen J, Lu Y, Takata Y, Mehdizadeh A, Chang GJ, Rodriguez-Bigas MA, Li Y, Chang P, Mao Y, Hassan MM, Wang F, Li D. Serum exosomal miR-4772-3p is a predictor of tumor recurrence in stage II and III colon cancer. Oncotarget 7(46):76250-76260, 2016. e-Pub 2016. PMID: 27788488.
63. Yamashita S, Vauthey JN, Kaseb AO, Aloia TA, Conrad C, Hassan MM, Passot G, Raghav KP, Shama MA, Chun YS. Prognosis of Fibrolamellar carcinoma compared to non-cirrhotic conventional hepatocellular carcinoma. J Gastrointest Surg 20(10):1725-31, 2016. e-Pub 2016. PMID: 27456016.
64. Kaseb AO, Hassan MM, Lacin S, Abdel-Wahab R, Amin HM, Shalaby A, Wolff RA, Yao J, Rashid A, Vennapusa B, Feng J, Ohtomo T. Evaluating clinical and prognostic implications of Glypican-3 in hepatocellular carcinoma. Oncotarget 7(43):69916-69926, 2016. e-Pub 2016. PMID: 27655712.
65. Zhang M, Wang Z, Obazee O, Jia J, Childs EJ, Hoskins J, Figlioli G, Mocci E, Collins I, Chung CC, Hautman C, Arslan AA, Beane-Freeman L, Bracci PM, Buring J, Duell EJ, Gallinger S, Giles GG, Goodman GE, Goodman PJ, Kamineni A, Kolonel LN, Kulke MH, Malats N, Olson SH, Sesso HD, Visvanathan K, White E, Zheng W, Abnet CC, Albanes D, Andreotti G, Brais L, Bueno-de-Mesquita HB, Basso D, Berndt SI, Boutron-Ruault MC, Bijlsma MF, Brenner H, Burdette L, Campa D, Caporaso NE, Capurso G, Cavestro GM, Cotterchio M, Costello E, Elena J, Boggi U, Gaziano JM, Gazouli M, Giovannucci EL, Goggins M, Gross M, Haiman CA, Hassan MM, Helzlsouer KJ, Hu N, Hunter DJ, Iskierka-Jazdzewska E, Jenab M, Kaaks R, Key TJ, Khaw KT, Klein EA, Kogevinas M, Krogh V, Kupcinskas J, Kurtz RC, Landi MT, Landi S, Le Marchand L, Mambrini A, Mannisto S, Milne RL, Neale RE, Oberg AL, Panico S, Patel AV, Peeters PH, Peters U, Pezzilli R, Porta M, Purdue M, Quiros JR, Riboli E, Rothman N, Scarpa A, Scelo G, Shu XO, Silverman DT, Soucek P, Strobel O, Sund M, Malecka-Panas E, Taylor PR, Tavano F, Travis RC, Thornquist M, Tjønneland A, Tobias GS, Trichopoulos D, Vashist Y, Vodicka P, Wactawski-Wende J, Wentzensen N, Yu H, Yu K, Zeleniuch-Jacquotte A, Kooperberg C, Risch HA, Jacobs EJ, Li D, Fuchs C, Hoover R, Hartge P, Chanock SJ, Petersen GM, Stolzenberg-Solomon RS, Wolpin BM, Kraft P, Klein AP, Canzian F, Amundadottir LT. Three new pancreatic cancer susceptibility signals identified on chromosomes 1q32.1, 5p15.33 and 8q24.21. Oncotarget 7(41):66328-66343, 2016. e-Pub 2016. PMID: 27579533.
66. Sohn BH, Shim JJ, Kim SB, Jang KY, Kim SM, Kim JH, Hwang JE, Jang HJ, Lee HS, Kim SC, Jeong W, Kim SS, Park ES, Heo J, Kim YJ, Kim DG, Leem SH, Kaseb A, Hassan MM, Cha M, Chu IS, Johnson RL, Park YY, Lee JS. Inactivation of Hippo Pathway is Significantly Associated with Poor Prognosis in Hepatocellular Carcinoma. Clin Cancer Res 22(5):1256-64, 2016. e-Pub 2016. PMID: 26459179.
67. Mahvash A, Murthy R, Odisio BC, Raghav KP, Girard L, Cheung S, Nguyen V, Ensor J, Gadani S, Elsayes KM, Abdel-Wahab R, Hassan M, Shalaby AS, Yao JC, Wallace MJ, Kaseb AO. Yttrium-90 resin microspheres as an adjunct to sorafenib in patients with unresectable hepatocellular carcinoma. J Hepatocell Carcinoma 2016:3:1-3, 2016. e-Pub 2016. PMID: 27574586.
68. Kaseb AO, Morris JS, Iwasaki M, Al-Shamsi HO, Raghav KP, Girard L, Cheung S, Nguyen V, Elsayes KM, Xiao L, Abdel-Wahab R, Shalaby AS, Hassan MM, Hassabo HM, Wolff RA, Yao JC. Phase II trial of bevacizumab and erlotinib as a second-line therapy for advanced hepatocellular carcinoma. Onco Targets Ther 9:773-80, 2016. e-Pub 2016. PMID: 26929648.
69. Sampson JN, Wheeler WA, Yeager M, Panagiotou O, Wang Z, Berndt SI, Lan Q, Abnet CC, Amundadottir LT, Figueroa JD, Landi MT, Mirabello L, Savage SA, Taylor PR, De Vivo I, McGlynn KA, Purdue MP, Rajaraman P, Adami HO, Ahlbom A, Albanes D, Amary MF, An SJ, Andersson U, Andriole G, Andrulis IL, Angelucci E, Ansell SM, Arici C, Armstrong BK, Arslan AA, Austin MA, Baris D, Barkauskas DA, Bassig BA, Becker N, Benavente Y, Benhamou S, Berg C, Van Den Berg D, Bernstein L, Bertrand KA, Birmann BM, Black A, Boeing H, Boffetta P, Boutron-Ruault MC, Bracci PM, Brinton L, Brooks-Wilson AR, Bueno-de-Mesquita HB, Burdett L, Buring J, Butler MA, Cai Q, Cancel-Tassin G, Canzian F, Carrato A, Carreon T, Carta A, Chan JK, Chang ET, Chang GC, Chang IS, Chang J, Chang-Claude J, Chen CJ, Chen CY, Chen C, Chen CH, Chen C, Chen H, Chen K, Chen KY, Chen KC, Chen Y, Chen YH, Chen YS, Chen YM, Chien LH, Chirlaque MD, Choi JE, Choi YY, Chow WH, Chung CC, Clavel J, Clavel-Chapelon F, Cocco P, Colt JS, Comperat E, Conde L, Connors JM, Conti D, Cortessis VK, Cotterchio M, Cozen W, Crouch S, Crous-Bou M, Cussenot O, Davis FG, Ding T, Diver WR, Dorronsoro M, Dossus L, Duell EJ, Ennas MG, Erickson RL, Feychting M, Flanagan AM, Foretova L, Fraumeni JF, Freedman ND, Beane Freeman LE, Fuchs C, Gago-Dominguez M, Gallinger S, Gao YT, Gapstur SM, Garcia-Closas M, García-Closas R, Gascoyne RD, Gastier-Foster J, Gaudet MM, Gaziano JM, Giffen C, Giles GG, Giovannucci E, Glimelius B, Goggins M, Gokgoz N, Goldstein AM, Gorlick R, Gross M, Grubb R, Gu J, Guan P, Gunter M, Guo H, Habermann TM, Haiman CA, Halai D, Hallmans G, Hassan M, Hattinger C, He Q, He X, Helzlsouer K, Henderson B, Henriksson R, Hjalgrim H, Hoffman-Bolton J, Hohensee C, Holford TR, Holly EA, Hong YC, Hoover RN, Horn-Ross PL, Hosain GM, Hosgood HD, Hsiao CF, Hu N, Hu W, Hu Z, Huang MS, Huerta JM, Hung JY, Hutchinson A, Inskip PD, Jackson RD, Jacobs EJ, Jenab M, Jeon HS, Ji BT, Jin G, Jin L, Johansen C, Johnson A, Jung YJ, Kaaks R, et al. Analysis of Heritability and Shared Heritability Based on Genome-Wide Association Studies for Thirteen Cancer Types. J Natl Cancer Inst 107(12):djv279, 2015. e-Pub 2015. PMID: 26464424.
70. Abdel-Wahab R, Shehata S, Hassan MM, Xiao L, Lee JS, Cheung S, Essa HH, Hassabo HM, Shalaby AS, Mosad E, Raghav K, Rashid A, Wolff RA, Morris JS, Amin HM, Kaseb AO. Validation of an IGF-CTP scoring system for assessing hepatic reserve in Egyptian patients with hepatocellular carcinoma. Oncotarget 6(25):21193-207, 2015. e-Pub 2015. PMID: 26098859.
71. Hassan MM, Abdel-Wahab R, Kaseb A, Shalaby A, Phan AT, El-Serag HB, Hawk E, Morris J, Singh Raghav KP, Lee JS, Vauthey JN, Bortus G, Torres HA, Amos CI, Wolff RA, Li D. Obesity Early in Adulthood Increases Risk but Does Not Affect Outcomes of Hepatocellular Carcinoma. Gastroenterology 149(15):447-3, 2015. e-Pub 2015. PMID: 25836985.
72. Mahale P, Kaseb AO, Hassan MM, Torres HA. Hepatocellular carcinoma as a second primary cancer in patients with chronic hepatitis C virus infection. Dig Liver Dis 47(4):348-9, 2015. e-Pub 2015. PMID: 25563811.
73. Li D, Mao Y, Chang P, Liu C, Hassan MM, Yeung SJ, Abbruzzese JL. Impacts of new-onset and long-term diabetes on clinical outcome of pancreatic cancer. Am J Cancer Res 5(10):3260-9, 2015. e-Pub 2015. PMID: 26693076.
74. Childs EJ, Mocci E, Rizzato C, Bracci PM, Gallinger S, Goggins MG, Li D, Neale R, Olson SH, Scelo G, Bamlet WR, Blackford A, Borges M, Brennan P, Canzian F, Campa D, Cleary SP, Chaffee KG, Cotterchio M, Foretova L, Hassan M, Holcatova I, Holly EA, Janout V, Kurtz RC, Lu L, Oberg AL, Orlow I, Saldia A, Yu H, Petersen GM, Risch H, Klein AP. Pancreatic Cancer associated with variation on 17q25.1, 3q29, 7p13, and 2p13.3: a PanC4 Study. Nature Genetics 47(8):911-6, 2015. e-Pub 2015.
75. Arem H, Yu K, Xiong X, Moy K, Freedman ND, Mayne ST, Albanes D, Arslan AA, Austin M, Bamlet WR, Beane-Freeman L, Bracci P, Canzian F, Cotterchio M, Duell EJ, Gallinger S, Giles GG, Goggins M, Goodman PJ, Hartge P, Hassan MM, Helzlsouer K, Henderson B, Holly EA, Hoover R, Jacobs EJ, Kamineni A, Klein A, Klein E, Kolonel LN, Li D, Malats N, Männistö S, McCullough ML, Olson SH, Orlow I, Peters U, Petersen GM, Porta M, Severi G, Shu XO, Visvanathan K, White E, Yu H, Zeleniuch-Jacquotte A, Zheng W, Tobias GS, Maeder D, Brotzman M, Risch H, Sampson JN, Stolzenberg-Solomon RZ. Vitamin D metabolic pathway genes and pancreatic cancer risk. PLoS One 23(10):3, 2015. e-Pub 2015. PMID: 25799011.
76. Wolpin BM, Rizzato C, Kraft P, Kooperberg C, Petersen GM, Wang Z, Arslan AA, Beane-Freeman L, Bracci PM, Buring J, Canzian F, Duell EJ, Gallinger S, Giles GG, Goodman GE, Goodman PJ, Jacobs EJ, Kamineni A, Klein AP, Kolonel LN, Kulke MH, Li D, Malats N, Olson SH, Risch HA, Sesso HD, Visvanathan K, White E, Zheng W, Abnet CC, Albanes D, Andreotti G, Austin MA, Barfield R, Basso D, Berndt SI, Boutron-Ruault MC, Brotzman M, Büchler MW, Bueno-de-Mesquita HB, Bugert P, Burdette L, Campa D, Caporaso NE, Capurso G, Chung C, Cotterchio M, Costello E, Elena J, Funel N, Gaziano JM, Giese NA, Giovannucci EL, Goggins M, Gorman MJ, Gross M, Haiman CA, Hassan MM, Helzlsouer KJ, Henderson BE, Holly EA, Hu N, Hunter DJ, Innocenti F, Jenab M, Kaaks R, Key TJ, Khaw KT, Klein EA, Kogevinas M, Krogh V, Kupcinskas J, Kurtz RC, LaCroix A, Landi MT, Landi S, Le Marchand L, Mambrini A, Mannisto S, Milne RL, Nakamura Y, Oberg AL, Owzar K, Patel AV, Peeters PH, Peters U, Pezzilli R, Piepoli A, Porta M, Real FX, Riboli E, Rothman N, Scarpa A, Shu XO, Silverman DT, Soucek P, Sund M, Talar-Wojnarowska R, Taylor PR, Theodoropoulos GE, Thornquist M, Tjønneland A, Tobias GS, Trichopoulos D, Vodicka P, Wactawski-Wende J, Wentzensen N, Wu C, Yu H, Yu K, Zeleniuch-Jacquotte A, Hoover R, Hartge P, Fuchs C, Chanock SJ, Stolzenberg-Solomon RS, Amundadottir LT. Genome-wide association study identifies multiple susceptibility loci for pancreatic cancer. Nat Genet 46(9):994-1000, 2014. e-Pub 2014. PMID: 25086665.
77. Kaseb AO, Xiao L, Hassan MM, Chae YK, Lee JS, Vauthey JN, Krishnan S, Cheung S, Hassabo HM, Aloia T, Conrad C, Curley SA, Vierling JM, Jalal P, Raghav K, Wallace M, Rashid A, Abbruzzese JL, Wolff RA, Morris JS. Development and validation of insulin-like growth factor-1 score to assess hepatic reserve in hepatocellular carcinoma. J Natl Cancer Inst 9(106):5, 2014. e-Pub 2014. PMID: 24815863.
78. Kaseb AO, Shah NN, Hassabo HM, Morris JS, Xiao L, Abaza YM, Soliman K, Lee JS, Vauthey JN, Wallace M, Aloia TA, Curley S, Abbruzzese JL, Hassan MM. Reassessing hepatocellular carcinoma staging in a changing patient population. Oncology 86(2):63-71, 2014. e-Pub 2014. PMID: 24401634.
79. Hassan MM, Kaseb A, Etzel CJ, El-Serag H, Spitz MR, Chang P, Hale KS, Liu M, Rashid A, Shama M, Abbruzzese JL, Loyer EM, Kaur H, Hassabo HM, Vauthey JN, Wray CJ, Hassan BS, Patt YZ, Hawk E, Soliman KM, Li D. Genetic Variation in the PNPLA3 Gene and Hepatocellular Carcinoma in USA: Risk and Prognosis Prediction. Mol Carcinog 52(Suppl 1):E139-47, 2013. e-Pub 2013. PMID: 23776098.
80. Kaseb AO, Shindoh J, Patt YZ, Roses RE, Zimmitti G, Lozano RD, Hassan MM, Hassabo HM, Curley SA, Aloia TA, Abbruzzese JL, Vauthey JN. Modified cisplatin/interferon α-2b/doxorubicin/5-fluorouracil (PIAF) chemotherapy in patients with no hepatitis or cirrhosis is associated with improved response rate, resectability, and survival of initially unresectable hepatocellular carcinoma. Cancer 119(18):3334-42, 2013. e-Pub 2013. PMID: 23821538.
81. Deng Y, Hassan MM, Mo J, Lin EH. Peripheral blood mononuclear CD133 mRNA levels correlates with response to treatment in patients with gastrointestinal stromal tumors. PLoS One 8(2):e55520, 2013. e-Pub 2013. PMID: 23408993.
82. Klein AP, Lindström S, Mendelsohn JB, Steplowski E, Arslan AA, Bueno-de-Mesquita HB, Fuchs CS, Gallinger S, Gross M, Helzlsouer K, Holly EA, Jacobs EJ, Lacroix A, Li D, Mandelson MT, Olson SH, Petersen GM, Risch HA, Stolzenberg-Solomon RZ, Zheng W, Amundadottir L, Albanes D, Allen NE, Bamlet WR, Boutron-Ruault MC, Buring JE, Bracci PM, Canzian F, Clipp S, Cotterchio M, Duell EJ, Elena J, Gaziano JM, Giovannucci EL, Goggins M, Hallmans G, Hassan MM, Hutchinson A, Hunter DJ, Kooperberg C, Kurtz RC, Liu S, Overvad K, Palli D, Patel AV, Rabe KG, Shu XO, Slimani N, Tobias GS, Trichopoulos D, Van Den Eeden SK, Vineis P, Virtamo J, Wactawski-Wende J, Wolpin BM, Yu H, Yu K, Zeleniuch-Jacquotte A, Chanock SJ, Hoover RN, Hartge P, Kraft P. An absolute risk model to identify individuals at elevated risk for pancreatic cancer in the general population. PLoS One 8(9):e72311, 2013. e-Pub 2013. PMID: 24058443.
83. Kaseb AO, Shama M, Sahin IH, Nooka A, Hassabo HM, Vauthey JN, Aloia T, Abbruzzese JL, Subbiah IM, Janku F, Curley S, Hassan MM. Prognostic indicators and treatment outcome in 94 cases of fibrolamellar hepatocellular carcinoma. Oncology 85(4):197-203, 2013. e-Pub 2013. PMID: 24051705.
84. Sahin IH, Shama MA, Tanaka M, Abbruzzese JL, Curley SA, Hassan MM, Li D. Association of diabetes and perineural invasion in pancreatic cancer. Cancer Med 1(3):357-62, 2012. e-Pub 2012. PMID: 23342285.
85. Serra S, Zheng L, Hassan MM, Phan AT, Woodhouse LJ, Yao JC, Ezzat S, Asa SL. The FGFR4-G388R Single-nucleotide polymorphism alters pancreatic neuroendocrine tumor progression and response to mTOR inhibition therapy. Cancer Res 72(22):5683-91, 2012. e-Pub 2012. PMID: 22986737.
86. Bosetti C, Lucenteforte E, Silverman DT, Petersen G, Bracci PM, Ji BT, Negri E, Li D, Risch HA, Olson SH, Gallinger S, Miller AB, Bueno-de-Mesquita HB, Talamini R, Polesel J, Ghadirian P, Baghurst PA, Zatonski W, Fontham E, Bamlet WR, Holly EA, Bertuccio P, Gao YT, Hassan MM, Yu H, Kurtz RC, Cotterchio M, Su J, Maisonneuve P, Duell EJ, Boffetta P, La Vecchia C. Cigarette Smoking and Pancreatic Cancer: An Analysis from the International Pancreatic Cancer Case-Control Consortium (PanC4). Ann Oncol 23(7):1880-8, 2012. e-Pub 2012. PMID: 22104574.
87. Torres HA, Nevah MI, Barnett BJ, Mahale P, Kontoyiannis DP, Hassan MM, Raad II. Hepatitis C virus genotype distribution varies by underlying disease status among patients in the same geographic region: a retrospective multicenter study. J Clin Virol 54(3):218-22, 2012. e-Pub 2012. PMID: 22459004.
88. Sadeghi N, Abbruzzese JL, Yeung SC, Hassan MM, Li D. Metformin use is associated with better survival of diabetic patients with pancreatic cancer. Clin Cancer Res 18(10):2905-12, 2012. e-Pub 2012. PMID: 22465831.
89. Jacobs KB, Yeager M, Zhou W, Wacholder S, Wang Z, Rodriguez-Santiago B, Hutchinson A, Deng X, Liu C, Horner MJ, Cullen M, Epstein CG, Burdett L, Dean MC, Chatterjee N, Sampson J, Chung CC, Kovaks J, Gapstur SM, Stevens VL, Teras LT, Gaudet MM, Albanes D, Weinstein SJ, Virtamo J, Taylor PR, Freedman ND, Abnet CC, Goldstein AM, Hu N, Yu K, Yuan JM, Liao L, Ding T, Qiao YL, Gao YT, Koh WP, Xiang YB, Tang ZZ, Fan JH, Aldrich MC, Amos C, Blot WJ, Bock CH, Gillanders EM, Harris CC, Haiman CA, Henderson BE, Kolonel LN, Le Marchand L, McNeill LH, Rybicki BA, Schwartz AG, Signorello LB, Spitz MR, Wiencke JK, Wrensch M, Wu X, Zanetti KA, Ziegler RG, Figueroa JD, Garcia-Closas M, Malats N, Marenne G, Prokunina-Olsson L, Baris D, Schwenn M, Johnson A, Landi MT, Goldin L, Consonni D, Bertazzi PA, Rotunno M, Rajaraman P, Andersson U, Beane Freeman LE, Berg CD, Buring JE, Butler MA, Carreon T, Feychting M, Ahlbom A, Gaziano JM, Giles GG, Hallmans G, Hankinson SE, Hartge P, Henriksson R, Inskip PD, Johansen C, Landgren A, McKean-Cowdin R, Michaud DS, Melin BS, Peters U, Ruder AM, Sesso HD, Severi G, Shu XO, Visvanathan K, White E, Wolk A, Zeleniuch-Jacquotte A, Zheng W, Silverman DT, Kogevinas M, Gonzalez JR, Villa O, Li D, Duell EJ, Risch HA, Olson SH, Kooperberg C, Wolpin BM, Jiao L, Hassan M, Wheeler W, Arslan AA, Bueno-de-Mesquita HB, Fuchs CS, Gallinger S, Gross MD, Holly EA, Klein AP, LaCroix A, Mandelson MT, Petersen G, Boutron-Ruault MC, Bracci PM, Canzian F, Chang K, Cotterchio M, Giovannucci EL, Goggins M, Hoffman Bolton JA, Jenab M, Khaw KT, Krogh V, Kurtz RC, McWilliams RR, Mendelsohn JB, Rabe KG, Riboli E, Tjønneland A, Tobias GS, Trichopoulos D, Elena JW, Yu H, Amundadottir L, Stolzenberg-Solomon RZ, Kraft P, Schumacher F, Stram D, Savage SA, Mirabello L, Andrulis IL, Wunder JS, Patiño García A, Sierrasesúmaga L, Barkauskas DA, Gorlick RG, Purdue M, Chow WH, Moore LE, Schwartz KL, Davis FG, Hsing AW, Berndt SI, Black A, Wentzensen N, Brinton LA, et al. Detectable clonal mosaicism and its relationship to aging and cancer. Nat Genet 44(6):651-8, 2012. e-Pub 2012. PMID: 22561519.
90. Garrett CR, Hassabo HM, Bhadkamkar NA, Wen S, Baladandayuthapani V, Kee BK, Eng C, Hassan MM. Survival advantage observed with the use of metformin in patients with type II diabetes and colorectal cancer. Br J Cancer 106(8):1374-8, 2012. e-Pub 2012. PMID: 22421948.
91. Lucenteforte E, La Vecchia C, Silverman D, Petersen GM, Bracci PM, Ji BT, Bosetti C, Li D, Gallinger S, Miller AB, Bueno-de-Mesquita HB, Talamini R, Polesel J, Ghadirian P, Baghurst PA, Zatonski W, Fontham E, Bamlet WR, Holly EA, Gao YT, Negri E, Hassan MM, Cotterchio M, Su J, Maisonneuve P, Boffetta P, Duell EJ. Alcohol consumption and pancreatic cancer: a pooled analysis in the International Pancreatic Cancer Case-Control Consortium (PanC4). Ann Oncol 23(2):374-82, 2012. e-Pub 2012. PMID: 21536662.
92. Kaseb AO, Garrett-Mayer E, Morris JS, Xiao L, Lin E, Onicescu G, Hassan MM, Hassabo HM, Iwasaki M, Deaton FL, Abbruzzese JL, Thomas MB. Efficacy and predictors of outcome of bevacizumab plus erlotinib for advanced hepatocellular carcinoma: final results of a phase II trial. Oncology 82(2):67-74, 2012. e-Pub 2012. PMID: 22327795.
93. Kaseb AO, Morris JS, Hassan MM, Siddiqui AM, Lin E, Xiao L, Abdalla EK, Vauthey JN, Aloia TA, Krishnan S, Abbruzzese JL. Clinical and Prognostic Implications of Plasma IGF-1 and VEGF in Patients with Hepatocellular Carcinoma. J Clin Oncol 29(29):3892-9, 2011. e-Pub 2011. PMID: 21911725.
94. Bertuccio P, La Vecchia C, Silverman DT, Petersen GM, Bracci PM, Negri E, Li D, Risch HA, Olson SH, Gallinger S, Miller AB, Bueno-de-Mesquita HB, Talamini R, Polesel J, Ghadirian P, Baghurst PA, Zatonski W, Fontham ET, Bamlet WR, Holly EA, Lucenteforte E, Hassan MM, Yu H, Kurtz RC, Cotterchio M, Su J, Maisonneuve P, Duell EJ, Bosetti C, Boffetta P. Cigar and pipe smoking, smokeless tobacco use and pancreatic cancer: an analysis from the International Pancreatic Cancer Case-Control Consortium (PanC4). Ann Oncol 22(6):1420-6, 2011. e-Pub 2011. PMID: 21245160.
95. Tang H, Dong X, Hassan MM, Abbruzzese JL, Li D. Body mass index and obesity- and diabetes-associated genotypes and risk for pancreatic cancer. Cancer Epidemiol Biomarkers Prev 20(5):779-92, 2011. e-Pub 2011. PMID: 21357378.
96. Li D, Tang H, Hassan MM, Holly EA, Bracci PM, Silverman DT. Diabetes and Risk of Pancreatic Cancer: a Pooled Analysis of Three Large Case-Control Studies. Cancer Causes Control 22(2):189-197, 2011. e-Pub 2011. PMID: 21104117.
97. Walsh KM, Choi M, Oberg K, Kulke MH, Yao JC, Wu C, Jurkiewicz M, Hsu LI, Hooshmand SM, Hassan MM, Janson ET, Cunningham JL, Vosburgh E, Sackler RS, Lifton RP, Dewan AT, Hoh J. A pilot genome-wide association study shows genomic variants enriched in the non-tumor cells of patients with well-differentiated neuroendocrine tumors of the ileum. Endocr Relat Cancer 18(1):171-80, 2011. e-Pub 2011. PMID: 21139019.
98. Kaseb AO, Abbruzzese JL, Vauthey JN, Aloia TA, Abdalla EK, Hassan MM, Lin E, Xiao L, El-Deeb AS, Rashid A, Morris JS. I-CLIP: Improved Stratification of Advanced Hepatocellular Carcinoma Patients by Integrating Plasma IGF-1 into CLIP score. Oncology 80(5-6):373-81, 2011. e-Pub 2011. PMID: 21822028.
99. Kaseb AO, Hassan MM, Lin E, Xiao L, Kumar V, Pathak P, Lozano R, Rashid A, Abbruzzese JL, Morris JS. V-Clip: Integrating plasma vascular endothelial growth factor into a new scoring system to stratify patients with advanced hepatocellular carcinoma for clinical trials. Cancer 117(11):2478-2488, 2011. e-Pub 2011. PMID: 21157958.
100. Tang H, Dong X, Day RS, Hassan MM, Li D. Antioxidant Genes, Diabetes and Dietary Antioxidants in Association with Risk of Pancreatic Cancer. Carcinogenesis 31(4):607-13, 2010. e-Pub 2010. PMID: 20097730.
101. Hassan MM, Curley SA, Li D, Kaseb A, Davila M, Abdalla EK, Javle M, Moghazy DM, Lozano RD, Abbruzzese JL, Vauthey JN. Duration of Diabetes and type of diabetes treatment, increase the risk of hepatocellular carcinoma. Cancer 116(8):1938-46, 2010. e-Pub 2010. PMID: 20166205.
102. Petersen GM, Amundadottir L, Fuchs CS, Kraft P, Stolzenberg-Solomon RZ, Jacobs K, Arslan AA, Bueno-de-Mesquita HB, Gallinger S, Gross M, Helzlsouer K, Holly EA, Jacobs EA, Klein AP, LaCroix A, Li D, Mandelson MT, Olson SH, Risch HA, Zheng W, Albanes D, Bamlet WR, Berg CD, Bourtron-Ruault M, Buring JE, Bracci PM, Canzian F, Clipp S, Cotterchio M, de Andrade M, Duell EJ, Gaziano JM, Giovannucci EL, Goggins M, Hallmans G, Hankinson SE, Hassan M, Howard B, Hunter DJ, Hutchinson A, Jenab M, Kaaks R, Kooperberg C, Krogh V, Hurtz RC, Lynch SM, McWilliams RR, Mendelsohn JB, Michaud DS, Parikh H, Patel AV, Peeters PH, Rajkovic A, Riboli E, Rodriguez L, Seminara D, Shu X, Thomas G, Tjonneland A, Tobias GS, Trichopoulos D, Van Den Eeden SK, Virtamo J, Wactawski-Wende J, Wang Z, Wolpin BM, Yu H, Yu K, Zeleniuch-Jacquotte A, Fraumeni Jr JF, Hoover RN, Hartge P, Chanock SJ. A genome-wide association study identifies pancreatic cancer susceptibility loci on chromosomes 13q22.1, 1q32.1 and 5p15.33. Nature Genetics 42(3):224-8, 2010. e-Pub 2010. PMID: 20101243.
103. Bracci PM, Wang F, Hassan MM, Gupta S, Li D, Holly EA. Pancreatitis and Pancreatic Cancer in Two Large Pooled Case-Control Studies. Cancer Causes Control 20(9):1723-1731, 2009. e-Pub 2009. PMID: 19760029.
104. Amundadottir L, Kraft P, Stolzenberg-Solomon RZ, Fuchs CS, Petersen GM, Arslan AA, Bueno-de-Mesquita HB, Gross M, Helzlsouer K, Jacobs EJ, LaCroix A, Zheng W, Albanes D, Bamlet W, Berg CD, Berrino F, Bingham S, Buring JE, Bracci PM, Canzian F, Clavel-Chapelon F, Clipp S, Cotterchio M, de Andrade M, Duell EJ, Fox JW, Gallinger S, Gaziano JM, Giovannucci EL, Goggins M, González CA, Hallmans G, Hankinson SE, Hassan MM, Holly EA, Hunter DJ, Hutchinson A, Jackson R, Jacobs KB, Jenab M, Kaaks R, Klein AP, Kooperberg C, Kurtz RC, Li D, Lynch SM, Mandelson M, McWilliams RR, Mendelsohn JB, Michaud DS, Olson SH, Overvad K, Patel AV, Peeters PH, Rajkovic A, Riboli E, Risch HA, Shu XO, Thomas G, Tobias GS, Trichopoulos D, Van Den Eeden SK, Virtamo J, Wactawski-Wende J, Wolpin BM, Yu H, Yu K, Zeleniuch-Jacquotte A, Chanock SJ, Hartge P, Hoover RN. Genome Wide Association Study Identifies ABO Blood Group Susceptibility Variants for Pancreatic Cancer. Nat Genet 41(9):986-90, 2009. e-Pub 2009. PMID: 19648918.
105. Li D, Yeung SC, Hassan MM, Konopleva M, Abbruzzese JL. Antidiabetic Therapies Affect Risk of Pancreatic Cancer. Gastroenterology 137(2):482-88, 2009. e-Pub 2009. PMID: 19375425.
106. Li D, Morris JS, Liu J, Hassan MM, Day RS, Bondy ML, Abbruzzese JL. Body Mass Index and Risk, Age of Onset, and Survival in Pancreatic Cancer Patients. JAMA 301(24):2553-62, 2009. e-Pub 2009. PMID: 19549972.
107. Hassan MM, Kaseb A, Li D, Patt YZ, Vauthey JN, Thomas MB, Curley SA, Spitz MR, Sherman SI, Abdalla EK, Davila M, Lozano RD, Hassan DM, Chan W, Brown TD, Abbruzzese JL. Association Between Hypothyroidism and Hepatocellular Carcinoma: A case-control study in the United States. Hepatology 49(5):1563-70, 2009. e-Pub 2009. PMID: 19399911.
108. Hassan MM, Spitz MR, Thomas MB, Curley SA, Patt YZ, Vauthey JN, Glover KY, Kaseb A, Lozano RD, El-Deeb AS, Nguyen NT, Wei SH, Chan W, Abbruzzese JL, Li D. The association of family history of liver cancer with hepatocellular carcinoma: a case-control study in the United States. J Hepatol 50(2):334-41, 2009. e-Pub 2009. PMID: 19070394.
109. Hwang JP, Hassan MM. Survival among Asian American with Hepatitis and Hepatocellular Carcinoma Referred to a Comprehensive Cancer Center in Texas. BMC Cancer 4(9):46, 2009. e-Pub 2009. PMID: 19193234.
110. Suzuki H, Li Y, Dong X, Hassan MM, Abbruzzese JL, Li D. Effect of Insulin-Like Growth Factor Gene Polymorphisms Alone or In Interaction with Diabetes on the Risk of Pancreatic Cancer. Cancer Epidemiol Biomarkers Prev 17(12):3467-73, 2008. e-Pub 2008. PMID: 19064563.
111. Hassan MM, Spitz MR, Thomas MB, El-Deeb AS, Glover KY, Nguyen NT, Chan W, Kaseb A, Curley SA, Vauthey JN, Ellis LM, Abdalla E, Lozano RD, Patt YZ, Brown TD, Abbruzzese JL, Li D. Effect of Different Types of Smoking and Synergism with Hepatitis C virus on Risk of Hepatocellular Carcinoma in American Men and Women: Case-Control Study. Int J Cancer 123(8):1883-1891, 2008. e-Pub 2008. PMID: 18688864.
112. Hassan MM, Li D, El-Deeb AS, Wolff RA, Bondy ML, Davila M, Abbruzzese JL. Hepatitis B Virus and Pancreatic Cancer. J Clin Oncol 26(28):4557-4562, 2008. e-Pub 2008. PMID: 18824707.
113. Hassan MM, Phan, Dagohoy C, Li D, Yao J. Risk Factors Associated with Carcinoids: A U.S.-Based Case-Control Study. Int J Cancer 123(4):867-873, 2008. e-Pub 2008.
114. Jiao L, Hassan MM, Bondy ML, Chang DZ, Abbruzzese JL, Evans D, Smolensky MH, Li D. XRCC2 and XRCC3 Gene Polymorphism and Risk of Pancreatic Cancer. AM J Gastroenterology 103(2):360-367, 2008. e-Pub 2008.
115. Li D, Hassan MM. Reply to passive smoking and the use of noncigarette tobacco products in association with risk for pancreatic cancer. Cancer 112(3):672-673, 2008. e-Pub 2008.
116. Suzuki H, Morris JS, Li Y, Doll MA, Hein DW, Liu J, Jiao L, Hassan MM, Day RS, Bondy ML, Abbruzzese JL, Li D. Interaction of the Cytochrome P4501A2, SULT1A1 and NAT Gene Polymorphisms with Smoking and Dietary Mutagen Intake in Modification of the Risk of Pancreatic Cancer. Carcinogenesis 29(6):1184-1191, 2008. e-Pub 2008.
117. Yao J, Hassan MM, Eisner MP, Leary C, Dagohoy C, Phan A, Rashid A, Evans D. One Hundred Years After "Carcinoid": One Hundred Years After: Epidemiology of and Prognostic Factors for Neuroendocrine Tumors in 38,825 Cases in the United States. Journal of Clinical Oncology 26(18):2063-2072, 2008. e-Pub 2008.
118. Hassan MM, Phan A, Dagohoy C, Li D, Yao J. Family History of Cancer and Risk of Neuroendocrine Tumors: Case-Control Study. Cancer Epidemiol. Biomarkers & Prev 17(4):959-965, 2008. e-Pub 2008.
119. Yao JC, Eisner MP, Leary C, Dagohoy C, Phan A, Rashid A, Hassan MM, Evans DB. Population-based study of islet cell carcinoma. Ann Surg Oncol 14(12):3492-500, 2007. e-Pub 2007. PMID: 17896148.
120. Hassan MM, Abbruzzese JL, Bondy ML, Wolff RA, Vauthey JN, Pisters PW, Evans DB, Khan R, Lenzi R, Jiao L, Li D. Passive smoking and the use of noncigarette tobacco products in association with risk for pancreatic cancer: a case-control study. Cancer 109(12):2547-56, 2007. e-Pub 2007. PMID: 17492688.
121. Shaib YH, El-Serag HB, Nooka AK, Thomas M, Brown TD, Patt YZ, Hassan MM. Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: a hospital-based case-control study. Am J Gastroenterol 102(5):1016-21, 2007. e-Pub 2007. PMID: 17324130.
122. Jiao L, Zhu J, Hassan MM, Evans DB, Abbruzzese JL, Li D. K-Ras mutation and p16 and preproenkephalin promoter hypermethylation in plasma DNA of pancreatic cancer patients: In relation to cigarette smoking. Pancreas 34(1):55-62, 2007. e-Pub 2007. PMID: 17198183.
123. Hassan MM, Bondy ML, Abbruzzese JL, Wolff RA, Vauthey GN, Pisters PW, Evans DB, Khan R, Chou TH, Lenzi LR, Jiao L, Li D. Risk Factors of Pancreatic Cancer. AM J Gastroenterology 102:1-12, 2007. e-Pub 2007.
124. Jiao L, Li D, Doll MA, Hein DW, Bondy ML, Hassan MM, Evans DB, Wolff RA, Lenzi R, Pisters PW, Abbruzzese JL, Li D. Haplotype of N-acetyltransferase 1 and 2 and risk of pancreatic cancer. Cancer Epidemiology, Biomarkers & Prevention 16(11):2379-2387, 2007. e-Pub 2007.
125. Li D, Day RS, Bondy ML, Sinha R, Nguyen NT, Evans BD, Abbruzzese J, Hassan MM. Dietary Mutagen Exposure and Risk of Pancreatic Cancer. Cancer Epidemiology, Biomarkers & Prevention 16(4):655-61, 2007. e-Pub 2007.
126. Lin EH, Hassan MM, Li Y, Zhao H, Nooka A, Sorenson E, Xie K, Champlin R, Wu X, Li D. Elevated circulating endothelial progenitor marker CD133 messenger RNA levels predict colon cancer recurrence. Cancer 110(3):534-542, 2007. e-Pub 2007.
127. Habib Y, El-Serag H, Thomas M, Hassan MM. HCV and Cholangiocarcinoma in USA, Case-Control Study. Am J Gastroenterol 102:1-6, 2007. e-Pub 2007.
128. Li D, Li Y, Jiao L, Chang DZ, Beinart G, Wolff RA, Evans DB, Hassan MM, Abbruzzese JL. Effects of base excision repair gene polymorphisms on pancreatic cancer survival. Int J Cancer 120(8):1748-54, 2007. e-Pub 2007.
129. Jiao, L, Bondy ML, Hassan MM, Chang DZ, Abbruzzese JL, Evans D, Smolensky MH, Li D. Gluthathione S-transferase gene polymorphisms and risk and survival of pancreatic cancer. Cancer 109(5):840-848, 2007. e-Pub 2007.
130. Hassan MM, Bondy ML, Abbruzzese JL, Wolff RA, Vauthey GN, Pisters PW, Evans DB, Khan R, Chou TH, Lenzi LR, Jiao L, Li D. Passive Smoking and Use of Non-Cigarette Tobacco Products in Association with Risk for Pancreatic Cancer: A Case-Control Study. Cancer 109(12):2547-56, 2007. e-Pub 2007.
131. Li D, Liu H, Jiao L, Chang DZ, Beinart G, Wolff RA, Evans DB, Hassan MM, Abbruzzese JL. Significant effects of homologous recombination DNA repair gene polymorphisms on pancreatic cancer survival. Cancer Res 66(6):3323-30, 2006. e-Pub 2006. PMID: 16540687.
132. Jiao L, Hassan MM, Bondy ML, Abbruzzese JL, Evans DB, Li D. The XPD Asp(312)Asn and Lys(751)Gln polymorphisms, corresponding haplotype, and pancreatic cancer risk. Cancer Lett, 2006. e-Pub 2006. PMID: 16458430.
133. Li D, Jiao L, Li Y, Doll MA, Hein DW, Bondy ML, Evans DB, Wolff RA, Lenzi R, Pisters PW, Abbruzzese JL, Hassan MM. Polymorphisms of cytochrome P4501A2 and N-acetyltransferase genes, smoking, and risk of pancreatic cancer. Carcinogenesis 27(1):103-11, 2006. e-Pub 2006. PMID: 15987714.
134. Jiao L, Bondy ML, Hassan MM, Wolff RA, Evans DB, Abbruzzese JL, Li D. Selected polymorphisms of DNA repair genes and risk of pancreatic cancer. Cancer Detect Prev 30(3):284-91, 2006. e-Pub 2006. PMID: 16844323.
135. Li D, Ahmed M, Li Y, Jiao L, Chou TH, Wolff RA, Lenzi R, Evans DB, Bondy ML, Pisters PW, Abbruzzese JL, Hassan MM. 5,10-Methylenetetrahydrofolate reductase polymorphisms and the risk of pancreatic cancer. Cancer Epidemiol Biomarkers Prev 14(6):1470-6, 2005. e-Pub 2005. PMID: 15941958.
136. Patt YZ, Hassan MM, Lozano RD, Nooka AK, Schnirer II, Zeldis JB, Abbruzzese JL, Brown TD. Thalidomide in the treatment of patients with hepatocellular carcinoma: a phase II trial. Cancer 103(4):749-55, 2005. e-Pub 2005. PMID: 15660400.
137. Patt YZ, Hassan MM, Aguayo A, Nooka AK, Lozano RD, Curley SA, Vauthey JN, Ellis LM, Schnirer II, Wolff RA, Charnsangavej C, Brown TD. Oral capecitabine for the treatment of hepatocellular carcinoma, cholangiocarcinoma, and gallbladder carcinoma. Cancer 101(3):578-86, 2004. e-Pub 2004. PMID: 15274071.
138. Yao JC, Wang L, Wei D, Gong W, Hassan MM, Wu TT, Mansfield P, Ajani J, Xie K. Association between expression of transcription factor Sp1 and increased vascular endothelial growth factor expression, advanced stage, and poor survival in patients with resected gastric cancer. Clin Cancer Res 10(12 Pt 1):4109-17, 2004. e-Pub 2004. PMID: 15217947.
139. Ahmed MI, Salahy EE, Tawfiq H, Khalifa A, Hassan MM. Matrix metalloproteinase-2, squamous cell carcinoma antigen, and tissue polypeptide-specific antigen expression in Egyptian patients with cervical carcinoma: Relationship with prognosis. Dis Markers 20(6):333-43, 2004. e-Pub 2004. PMID: 15665394.
140. Ghalib R, Levine C, Hassan MM, McClelland T, Goss J, Stribling R, Seu P, Patt YZ. Recombinant human interleukin-11 improves thrombocytopenia in patients with cirrhosis. Hepatology 37(5):1165-71, 2003. e-Pub 2003. PMID: 12717398.
141. Patt YZ, Hassan MM, Lozano RD, Brown TD, Vauthey JN, Curley SA, Ellis LM. Phase II trial of systemic continuous fluorouracil and subcutaneous recombinant interferon Alfa-2b for treatment of hepatocellular carcinoma. J Clin Oncol 21(3):421-7, 2003. e-Pub 2003. PMID: 12560429.
142. Hassan MM, Hwang LY, Hatten CJ, Swaim M, Li D, Abbruzzese JL, Beasley P, Patt YZ. Risk factors for hepatocellular carcinoma: synergism of alcohol with viral hepatitis and diabetes mellitus. Hepatology 36(5):1206-13, 2002. e-Pub 2002. PMID: 12395331.
143. Hassan MM, Frome A, Patt YZ, El-Serag HB. Rising prevalence of hepatitis C virus infection among patients recently diagnosed with hepatocellular carcinoma in the United States. J Clin Gastroenterol 35(3):266-9, 2002. e-Pub 2002. PMID: 12192205.
144. Firozi PF, Bondy ML, Sahin AA, Chang P, Lukmanji F, Singletary ES, Hassan MM, Li D. Aromatic DNA adducts and polymorphisms of CYP1A1, NAT2, and GSTM1 in breast cancer. Carcinogenesis 23(2):301-6, 2002. e-Pub 2002. PMID: 11872636.
145. Li D, Firozi PF, Zhang W, Shen J, DiGiovanni J, Lau S, Evans D, Friess H, Hassan MM, Abbruzzese JL. DNA adducts, genetic polymorphisms, and K-ras mutation in human pancreatic cancer. Mutat Res 513(1-2):37-48, 2002. e-Pub 2002. PMID: 11719088.
146. Patt YZ, Hassan MM, Lozano RD, Waugh KA, Hoque AM, Frome AI, Lahoti S, Ellis L, Vauthey JN, Curley SA, Schnirer II, Raijman I. Phase II trial of cisplatin, interferon alpha-2b, doxorubicin, and 5-fluorouracil for biliary tract cancer. Clin Cancer Res 7(11):3375-80, 2001. e-Pub 2001. PMID: 11705850.
147. Hassan MM, Zaghloul AS, El-Serag HB, Soliman O, Patt YZ, Chappell CL, Beasley RP, Hwang LY. The role of hepatitis C in hepatocellular carcinoma: a case control study among Egyptian patients. J Clin Gastroenterol 33(2):123-6, 2001. e-Pub 2001. PMID: 11468438.
148. Patt YZ, Hassan MM, Lozano RD, Ellis LM, Peterson JA, Waugh KA. Durable clinical response of refractory hepatocellular carcinoma to orally administered thalidomide. Am J Clin Oncol 23(3):319-21, 2000. e-Pub 2000. PMID: 10857902.
149. Wu X, Gu J, Patt Y, Hassan MM, Spitz MR, Beasley RP, Hwang LY. Mutagen sensitivity as a susceptibility marker for human hepatocellular carcinoma. Cancer Epidemiol Biomarkers Prev 7(7):567-70, 1998. e-Pub 1998. PMID: 9681523.
150. Squires RF, Saederup E, Lajtha A. Nonalcoholic steatohepatitis-related hepatocellular carcinoma: is there a role for the androgen receptor pathway?. J Neurochem 3(10):1403-1412, 1988. e-Pub 1988. PMID: 2842455.
151. Ahmed K, Fuentes D, Lin JS, Ali R, Kaseb AO, Hassan M, Szklaruk J, Hazle JD, Qayyum A, Elsayes KM. Volumetric Assessment of Hepatocellular Carcinoma Response to Treatment Using a Random Forest-Based Automated Segmentation Protocol. Cancer Medicine.
152. Yan D, Hassan M, Kaseb AO, Abdel-Wahab R, Li D. Telomere length and mitochondrial DNA copy number of variations as predictors for survival in hepatocellular carcinoma patients treated with sorafenib. Clinical Cancer Research.
153. Hassan MM, Abdel-Wahab R, Shehata S, Xiao L, Lee J, Cheung S, Essa HH, Shalaby AS, Mosad E, Raghav K, Rashid A, Wolff RA, Morris JS, Amin HM, Kaseb AO. GH/IGF axis is a prognostic indicator of HCC patients. Hepatology.
154. Abaza Y, Kaseb AO, Wahab AA, Sahin IH, Li D, Raghav K, Shalaby AS, Hassan MM. Occupational exposure as a risk factor for hepatocellular carcinoma: a case-control study in the United States. Occupational and Environmental Medicine.
155. Li D, Mao Y, Chang P, Hassan M, Yeung SJ, Abbruzzese JM. Characteristics and Impact of Diabetes Mellitus on Clinical Outcomes of Pancreatic Cancer. J Gastroent Hepatology.

Invited Articles

1. Phan AT, Oberg K, Choi J, Jr HL, Hassan MM, Strosberg JR, Krenning EP, Kocha W, Woltering EA, Maples WJ. NANETS Consensus Guideline for the Diagnosis and Management of Neuroendocrine Tumors: Well-Differentiated Neuroendocrine Tumors of the Thorax (Includes Lung and Thymus). Pancreas 39(6):784-798, 2010. e-Pub 2010. PMID: 20664476.
2. Boudreaux JP, Klimstra DS, Hassan MM, Woltering EA, Jensen RT, Goldsmith SJ, Nutting C, Bushnell DL, Caplin ME, Yao JC. The NANETS Consensus Guideline for the Diagnosis and Management of Neuroendocrine Tumors: Well-Differentiated Neuroendocrine Tumors of the Jejunum, Ileum, Appendix, and Cecum. Pancreas 39(6):753-766, 2010. e-Pub 2010. PMID: 20664473.

Review Articles

1. Elsheikh M, Sabagh AE, Mohamed IB, Bhongade M, Hassan MM, Jalal PK. Frailty in end-stage liver disease: Understanding pathophysiology, tools for assessment, and strategies for management. World journal of gastroenterology 29(46):6028-6048, 2023. e-Pub 2023. PMID: 38130738.
2. Yavuz BG, Datar S, Chamseddine S, Mohamed YI, LaPelusa M, Lee SS, Hu ZI, Koay EJ, Tran Cao HS, Jalal PK, Daniel-MacDougall C, Hassan M, Duda DG, Amin HM, Kaseb AO. The Gut Microbiome as a Biomarker and Therapeutic Target in Hepatocellular Carcinoma. Cancers (Basel) 15(19), 2023. e-Pub 2023. PMID: 37835569.
3. El Sabagh A, Mohamed IB, Aloor FZ, Abdelwahab A, Hassan MM, Jalal PK. Current Status of Biomarkers and Molecular Diagnostic Tools for Rejection in Liver Transplantation: Light at the End of the Tunnel?. Journal of Clinical and Experimental Hepatology 13(1):139-148, 2023. e-Pub 2023. PMID: 36647415.
4. Yavuz BG, Pestana RC, Abugabal YI, Krishnan S, Chen J, Hassan MM, Wolff RA, Rashid A, Amin HM, Kaseb AO. Origin and role of hepatic myofibroblasts in hepatocellular carcinoma. Oncotarget 11(13):1186-1201, 2020. e-Pub 2020. PMID: 32284794.
5. Abdel-Wahab R, Shehata S, Hassan MM, Habra MA, Eskandari G, Tinkey PT, Mitchell J, Lee JS, Amin HM, Kaseb AO. Type I insulin-like growth factor as a liver reserve assessment tool in hepatocellular carcinoma. J Hepatocell Carcinoma 2:131-142, 2015. e-Pub 2015. PMID: 27508202.
6. Sahin IH, Hassan MM, Garrett CR. Impact of non-steroidal anti-inflammatory drugs on gastrointestinal cancers: Current state-of-the science. Cancer Lett 345(2):249-57, 2014. e-Pub 2014. PMID: 24021750.
7. Kaseb AO, Hanbali A, Cotant M, Hassan MM, Wollner I, Philip PA. Vascular Endothelial Growth Factor in the Management of Hepatocellular Carcinoma. A Review Literature. Cancer 115(21):4895-906, 2009. e-Pub 2009. PMID: 19637355.

Other Articles

1. Ohannesian N, Mallick MS, He J, Qiao Y, Li N, Shaitelman SF, Tang C, Shinn EH, Hofstetter WL, Goltsov A, Hassan MM, Hunt KK, Lin SH, Shih W Author Correction: Plasmonic nano-aperture label-free imaging of single small extracellular vesicles for cancer detection. Communications Medicine 4(1), 2024. PMID: 38942807.

Abstracts

1. Hatia RI, Li D, Kaseb AO, MM <. The effect of circulating immune-related biomarkers on the risk of hepatocellular carcinoma. AASLD The Liver Meeting, Boston, MA Poster Presentation, 2023. e-Pub 2023.
2. Sabagh AE, Mohamed I, Hassan MM. Outcomes of Different Radiological Modalities for HCC Surveillance of High Risk Cirrhotic Patients. AASLD The Liver Meeting, 2022. e-Pub 2022.
3. Young H, Lewis R, McGlynn K, Hassan MM, Amos C. Multi-Trait Genome-Wide Joint Analyses Reveal New Susceptibility Loci and Predict Network-Based Proximity of Drugs to Primary Sclerosing Cholangitis. AASLD The Liver Meeting, 2022. e-Pub 2022.
4. Ahmed A, Hatia RI, Javle M, Jalal P, Amos C, Li D Hassan MM. Epidemiology and Risk Factors for Extrahepatic Cholangiocarcinoma in the Absence of Viral Hepatitis and Primary Sclerosing Cholangitis. AASLD The Liver Meeting, 2022. e-Pub 2022.
5. Mohamed I, Sabagh AE, Hassan MM, Jalal P. Presence of Infection in Patients with High Meld NA (>30) Predicts Worse Outcomes Post Liver Transplant. AASLD The Liver Meeting, 2022. e-Pub 2022.
6. Eluri M, Hatia RI, Javle M, Hassan MM. The association of family history of primary liver cancer with cholangiocarcinoma: USA case-control study. GI ASCO, 2021. e-Pub 2021.
7. Hamadeh GW, Lanka A, Shalaby A, Hatia R, Shalaby A, Khalifa A, Li D, Javle M, Hassan, MM. Multi-Factorial Etiology of Gallbladder Cancer: A USA Control-Case Study. DDW, 2021. e-Pub 2021.
8. Hassan M. FIB-4 and NAFLD Fibrosis Scores are Poor Predictors for Liver Fibrosis in Patients with Type 2 Diabetes Mellitus Abstract #24092. Hepatology Conference 2020 AASLD-2020-2920-1263-2156-5418 72:915A-916A, 2020. e-Pub 2020.
9. Hashim M, Moore WH, Hassan MM, Hoefs JC, Ismail MS, Jalal PK. Quantitative Liver Spleen Scan (QLSS) Can Predict the Outcome in Patines with Alcoholic Hepatitis: A Pilot Study Abstract #22737. Hepatology Conference 2020 Wiley AASLD-2020-7565-3929-1398-9929 72:188A-189A, 2020. e-Pub 2020.
10. Hatia RI, Javle M, Shroff R, Li D, Chang P, Karatas E, Uruba S, Jalal PK, Hashim M, Hassan MM. Estrogen Replacement Reduces Risk of Intrahepatic Cholangiocarcinoma in American Women Abstract #22241. Hepatology Conference 2020 Wiley AASLD-2020-3923-0442-6119-2869 72:635A, 2020. e-Pub 2020.
11. Hatia RI, Mohamed YI, Kaseb A, Morris JS, Li D, Chang P, Jalal PK, Hashim M, Hassan MM. The Effect of Circulating BDNF, TIMP-2, Fibronectin-C, and Chemerin on the Risk of Nonviral Hepatocellular Carcinoma Development in USA Abstract #24100. Hepatology Conference 2020 Wiley AASLD-2020-5029-97-6319-6677 72:672A-673A, 2020. e-Pub 2020.
12. Ismail MS, Sanchez J, Hassan M, Abdullah K, Jalal P, Egim C, Ankomasey V. Are There Demographic Variations between Obese and Non-Obese (Lean) Patients with Non-alcoholic Steatohepatitis?. Am J Gastroenterol, 2019. e-Pub 2019.
13. Ismail MS, M <, Dawood L, Patel K, Jalal P. Survival outcome after liver transplantation in US patients with hepatocellular carcinoma. J Hepatol 70(1):e561, 2019. e-Pub 2019.
14. Ismail MS, Hassan M, May S, Rana A, Jalal P. A higher prevalence of colorectal adenomatou polyps in patients with liver cirrhosis compared with non-cirhotics. J. Hepaol 70(1):e651, 2019. e-Pub 2019.
15. Al-Ass K, Kaseb A, Donghui L, Abdelkareem A, Yehia M, Ali R, Hassan. Gallbladder disease and the risk of hepatocellular carcinoma: US case-control study. AACR, Abstract Control 3717, 2019. e-Pub 2019.
16. Ismail, MS, Hassan M, Yousry WA, Kamal El-Din MM, Bahaa El-Din MM, El Sayed OA, Khaderi SA, Goss JA, Jalal P. Clinical Efficacy and Safety of Direct Acting Antivirals for Treatment of Hepatitis C Virus Recurrence after Liver Transplantation. AASLD 2019 Conference, Boston, 2019. e-Pub 2019.
17. Shalaby A, Javle M, Schroff R, Abdel-Wahab R, Hassan M. Early obesity and risk of cholangiocarcinoma in the United States. GI ASCO 2017, 2017. e-Pub 2017.
18. Abdel-Wahab R, Hassan M, Shalaby A, Lacin S, Raghav KP, Wolff R, Kaseb A. Association of elevated alpha-1 antitrypsin with advanced clinicopathologic features of hepatocellular carcinoma. GI ASCO 2017, 2017. e-Pub 2017.
19. Lacin S, Abdel-Wahab R, Elbanan M, Abdelbaki S, Shalaby AS, Hassan M, Wei W, Sun J, Elsayes KM, Kaseb AO. Impact of Sorafenib Treatment on Portal Hypertension in Hepatocellular Carcinoma Patients. ASCO. J Clin Oncol, 2017. e-Pub 2017.
20. Shalaby AS, Botrus G, Kaseb AO, Li D, Abdel-Wahab R, Wolff RA, Lacin S, Javle MM, Hawk E, Hassan M. The Protective Effect of Physical Activity on Risk of Hepatocellular Carcinoma in USA. ASCO. J Clin Oncol, 2017. e-Pub 2017.
21. Lacin S, Abdel-Wahab R, Hassan M, Shalaby AS, Amin HM, Wolff RA, Yao JC, Mistry A, Feng JD, Ohtomo T, Kaseb AO. Evaluating Clinical and Prognostic Implications of Glypican 3 in Hepatocellular Carcinoma. ASCO. J Clin Oncol, 2017. e-Pub 2017.
22. Abdel-Wahab R, Lacin S, Shalaby AS, Hassan M, Xiao L, Morris J, Amin HM, Kaseb AO. Impact of Integrating Insulin like growth factor-1 (IGF-1) in Model for End Stage Liver Disease (MELD) scores on Predicting Hepatocellular Carcinoma Patients' Survival. ASCO Annual Conference 2016, 2016. e-Pub 2016.
23. Abdel-Wahab R, Lacin S, Shalaby AS, Hassan M, Xiao L, Morris J, Amin HM, Kaseb AO. Integrating Insulin like growth factor-1 (IGF-1) score into Barcelona Clinic Liver Cancer (BCLC) and Cancer of the Liver Italian Program (CLIP) Scores. ASCO Annual Conference 2016, 2016. e-Pub 2016.
24. Hassan MM, Abdel-Wahab R. The Association Between Growth Hormone and Hepatocellular Carcinoma. American Associate to Study Liver Disease 2016 Annual Meeting, 2016. e-Pub 2016.
25. Hassan MM, Abdel-Wahab R. Status of Hepatocellular Carcinoma Screening in High Risk Population in the USA. American Association to Study Liver Disease 2016 Annual Meeting, 2016. e-Pub 2016.
26. Abdel-Wahab R, Eid SSM, Hassan M, Xiao L, Lee JS, Cheung SH, Hassabo HM, Shalaby AS, Essa HH, Mossad E, Raghav KPS, Rashid A, Wolff RA, Morris J, Amin HM, Kaseb AO. International validation of an IGF-CTP scoring system for assessing hepatic reserve in hepatocellular carcinoma. J Clin Oncol 33, 2015. e-Pub 2015.
27. Al-Shamsi HO, Abdel-Waha R, Hassan M, Botrus G, Shalaby AS, Wolff RA, Kaseb AO. Natural History of T1N0Mo Hepatocellular carcinoma: Large scale study in the United States. J Clin Oncol 33, 2015. e-Pub 2015.
28. Uemura MI, Kaseb AO, Abdel-Wahab R, Raghav KPS, Botrus G, Hawk E, Wolff RA, Morris J, Hassan M. Hepatitis B- and C-associated hepatocellular carcinoma in a large U.S. cancer center: Do clinicopathologic features or patient outcomes differ by the potentially causative viruses?. J Clin Oncol 33, 2015. e-Pub 2015.
29. Abdel-Wahab R, Hassan M, Raghav KPS, Shalaby AS, Botrus G, Xiao L, Morris J, Wolff RA, Kaseb AO. Single institutional experience of bevacizumab-based regimens in treatment of hepatocellular carcinoma. J Clin Oncol 33, 2015. e-Pub 2015.
30. Botrus G, Shalaby AS, Kaseb AO, Lenzi R, Abdel-Wahab R, Wolff RA, Hassan M. The protective effect of hormonal intake on risk of hepatocellular carcinoma in the United States. J Clin Oncol 33, 2015. e-Pub 2015.
31. Kaseb AO, Al-Shamsi HO, Morris J, Iwasaki M, Xiao L, Abdel-Wahab R, Raghav KPS, Hassan M, Hassabo HM, Wolff RA. Supplemental Abstr 4088. J Clin Oncol 33, 2015. e-Pub 2015.
32. Abdel Wahab R, Hassabo HM, El Antably A, Raghav K, Kaseb AO, Herlong HF, Chae YK, Botrus G, Torres HA, Shalaby AS, Hassan M. Prognostic Effect of Statins on Hepatocellular Carcinoma in Presence and Absence of Metformin. AASLD, 2014. e-Pub 2014.
33. Lenzi R, Coleman M, Xiao L, Abdel-Wahab R, Hassan M. Retrospective study to evaluate variables predicting no-show international patients. J Clin Oncol 32, 2014. e-Pub 2014.
34. Abdel-Wahab R, Hassan M, Eid SSM, Essa HH, Kaseb AO. The differential clinicopathologic features and survival outcome between hepatitis C-related HCC patients in the United States versus Egypt. J Clin Oncol 32, 2014. e-Pub 2014.
35. Hassan M, LiD, Kaseb A, Abbruzzese JL, Hassabo HM, Khalil M, Sahin I, Morris J, Hawk E, Spitz MR. Early Obesity and Risk of Hepatocellular Carcinoma in USA: Assessment of Environmental, Dietary, and Biological Risk Factors Impacting Liver Cancer Incidence in Texas. Society of Toxicology (SOT) Annual Meeting, 2013. e-Pub 2013.
36. Kaseb AO, Garrett-Mayer E, Morris JS, Xiao L, Lin E, Onicescu G, Hassan MM, Hassabo HM, Iwasaki M, Deaton FL, Abbruzzese JL, Thomas MB. Efficacy of bevacizumab plus erlotinib for advanced hepatocellular carcinoma and predictors of outcome: final results of a phase II trial. Oncology 82(2):67-74, 2012. e-Pub 2012. PMID: 22327795.
37. Chae YK, Kaseb AO, Mohamed H, Sahin IH, Khalil MF, Li D, Abbruzzese JL, Hassan M. The association between statin use and hepatocellular cancer outcome. J Clin Oncol 30: 2012 (Suppl 34; abstr 165) 2013 Gastrointestinal Cancers Symposium, 2012. e-Pub 2012.
38. Abouelezz K, Kaseb AO, Hassabo HM, Garrett CR, Vauthey NJ, Li D, Hassan M. Prognostic effect of angiotensin-converting-enzyme inhibitors in HCC patients treated with sorafenib. J Clin Oncol 30: 2012 (Suppl 34; abstr 328); 2013 Gastrointestinal Cancers Symposium, 2012. e-Pub 2012.
39. Shen Y, Sahin IH, Hassan M, Kee BK, Feig B, Ellis L, Aloia T, Abdalla E, Curley S, Vauthey JN, Garrett CR. Impact of smoking history on patient outcome following hepatic metastasectomy for colorectal cancer. J Clin Concol 30: 2012 (Suppl 34; abstr 517) 2013 Gastrointestinal Cancers Symposium, 2012. e-Pub 2012.
40. Bhadkamkar NA, Sahin IH, Shen Y, Hassabo HM, Kee BK, Hassan M, Garrett CR. Outcomes in patients (pts) with colorectal cancer (CRC) treated with oxaliplatin-based chemotherapy (OC) following prior oxaliplatin exposure. J Clin Oncol 30: 2012 (Suppl 34; abstr 500); 2013 Gastrointestinal Cancers Symposium, 2012. e-Pub 2012.
41. Mohamed H, Iwasaki M, Soliman K, Ahmed K, Torres HA, Li D, Xiao L, Abaza Y, Morris J, Hassan M. Impact of metformin on HCC prognosis in presence and absence of HCV infection. AACR 2012, 2012. e-Pub 2012.
42. Sahin IH, Hassabo HM, Shen Y, Kee BK, Hassan M, Garrett CR. Validation of the survival benefit from metformin use in patients with type 2 diabetes and colorectal cancer. J Clin Oncol 30: 2012 (Suppl 34; abstr 462); 2013 GI Cancers Symposium, 2012. e-Pub 2012.
43. Aly M, Sahin IH, Li D Khalil MF, Chang P, Fogelman DR, Javle M, Abbruzzese JL, Hassan M. Pancreatic injury, genetic variation of PNPLA3, and risk of pancreatic cancer. J Clin Oncol 30: 2012 (Suppl 34; abstr 141) 2013 Gastrointestinal Cancers Symposium, 2012. e-Pub 2012.
44. Kaseb AO, Siddiqui AM, Hassan MM, Lin E, Xiao L, Abbruzzese JL, Morris J. Use of IV-BCLC, a new molecular staging for hepatocellular carcinoma, for patient stratification. ASCO 2010, 2010. e-Pub 2010.
45. Hassabo H, Kaseb AO, Al-Kalla K, Shama M, Vauthey JN, Abdalla E, Lozano R, Patt YZ, Abbruzzese JL, Curley SA, Li D Hassan M. Association between prior history of cholecystectomy and hepatocellular carcinoma development: A case-control study in USA. ASCO 2010, 2010. e-Pub 2010.
46. Kaseb AO, Hassan M, Lin E, Xiao L, Kumar V, Lozano RD, Rashid A, Abbruzzese JL, Morris J. Effect of incorporating plasma VEGF level into a v-CLIP scoring system on stratification of patients with hepatocellular carcinoma. 2010 Gastrointestinal Cancers Symposium, 2010. e-Pub 2010.
47. Masood A, Siddiqui AM, Hassan M, Shama MA, Andejani A, Rashid A, Lozano RD, Abbruzzese JL, Kaseb AO. Prognostic effect of insulin growth factor-1 in hepatocellular carcinoma. 2010 Gastrointestinal Cancers Symposium, 2010. e-Pub 2010.
48. Shama MA, Kaseb AO, Vauthey J, Hassan M, Phan AT, Siddiqui AM, Nooka AK, Abbruzzese JL, Abdalla EK, Curley SA. Retrospective analyses of 52 patients with fibrolamellar hepatocellular carcinoma: Treatment outcome and prognostic indicators. 2010 Gastrointestinal Cancers Symposium, 2010. e-Pub 2010.
49. Li D, Morris J, Liu J, Hassan MM, Day RS, Bondy ML, Evans DB, Abbruzzese JL. Association of Body Mass Index with Risk, Age of Onset and Survival of Pancreatic Cancer. AACR, 2009. e-Pub 2009.
50. Hassan MM, Kaseb A, Li D, Moghazy D, Vauthey JN, Curley S, Abdalla EK, Abbruzzese JL. The association between diabetes mellitus and hepatocellular carcinoma. AACR, 2009. e-Pub 2009.
51. Hideo S, Li Y, Dong X, Hassan MM, Hyodo I, Abbruzzese JL, Li D. Effect of IGF gene polymorphisms alone or in interaction with diabetes on the risk of pancreatic cancer. AACR, 2009. e-Pub 2009.
52. Hideo S, Yanan L, Hassan MM, Bondy M, Abbruzzese JL, Li D, Jiao L, Doll M, Hein D, Day R. Interaction of the SULT1A1 and NAT gene polymorphisms with dietary mutagen intake in modification of the risk of pancreatic cancer. AACR, 2008. e-Pub 2008.
53. Li D, Suzuki H, Dong X, Okazaki T, Hassan MM, Abbruzzese JL, Li D. Insulin-like growth factor gene polymorphisms and risk of pancreatic cancer. AACR, 2008. e-Pub 2008.
54. Hassan MM, Thomas M, El-Deeb A, Spitz M, Nguyen N, Chan W, Glover K, Kaseb A, Brown T, Curley S, Vauthey JN, Abdalla E, Lozano R, Ellis L, Patt Y, Abbruzzese JL, Hassan D, Li D. Passive smoking and use of non-cigarette tobacco products in association with risk for hepatocellular carcinoma: A case-control study. AACR, 2008. e-Pub 2008.
55. Lin EH, Hassan MM, Li Y, Zhao H, Nooka A, Xie K, Champlin R, Wu X, Li D. Elevated stem cell marker CD133 mRNA in peripheral blood predicts colon cancer recurrence. ASCO, 2007. e-Pub 2007.
56. Hassan MM, Okazaki T, Jiao L, Steven C, Thomas M, Brown T, Vauthey N, Abdalla E, Patt YZ, Abbruzzese JL, Li D. Polymorphisms of manganese superoxide dismutase gene and susceptibility to hepatocellular carcinoma. AACR, 2007. e-Pub 2007.
57. Hassan MM, Okazaki T, Jiao L, Curley S, Thomas M, Brown TD, Vauthey J, Glover K, Abdalla E, Patt YZ, Abbruzzese JL, Li D. Polymorphisms of manganese superoxide dismutase gene and susceptibility to hepatocellular carcinoma. AACR, 2007. e-Pub 2007.
58. Nooka AK, Chang DZ, Abbruzzese JL, Evans DB, Wolff RA, MMb B, Li D. Impact of NAT1 polymorphism on survival of pancreatic cancer. ASCO, 2007. e-Pub 2007.
59. Hassan MM, Dagohoy C, Leary C, Li D, Yao JC. Risk factors for low-grade neuroendocrine carcinoma (LGNET): Hospital-based case-control study in US. ASCO, 2007. e-Pub 2007.
60. Li D, Hassan MM, Khan R, Bondy ML, Abbruzzese JL, Day RS. Dietary micronutrient intakes and risk of pancreatic cancer. AACR, 2007. e-Pub 2007.
61. Jiao L, Hassan MM, Chang DZ, Abbruzzese JL, Li D. Association of GSTP1, GSTM1, and GSTT1 polymorphisms with risk and overall survival of pancreatic cancer. AACR, 2006. e-Pub 2006.
62. Hassan MM, Khan R, Mestry K, Bondy ML, Abbruzzese JL, Evans D, Wolff RA, Chou TH, Ho L, Xiong HH, Lenzi R, Vauthey JN, Pisters PW, Li D. Risk factors of pancreatic cancer in the United States: Case-control study. AACR, 2006. e-Pub 2006.
63. Hassan MM, Li Y, Mestry K, Imam M, Bondy ML, Abbruzzese JL, Evans DB, Wolff RA, Chou T, Ho L, Xiong HQ, Lenzi R, Pisters PW, Li D. Genetic variations in MnSOD and CAT Genes and the risk of pancreatic cancer. AACR, 2005. e-Pub 2005.
64. Jiao L, Hassan MM, Frazier M, Evans DB, Abbruzzese JL, Li D. Genotype and hyplotype of XRCC2, XRCC3, and Rad54L genes and risk of pancreatic cancer. AACR, 2005. e-Pub 2005.
65. Li D, Hassan MM, Jiao L, Frazier M, Evans DB, Abbruzzese JL. DNA repair gene polymorphisms and risk of pancreatic cancer. AACR, 2005. e-Pub 2005.
66. Nooka A, Li D, Carson A, Wolff R, Abbruzzese JL, Evans DB, Pisters PW, Ho L, Lenzi R, Hassan MM. Assessing occupational risk for pancreatic cancer by chemical exposures and work history: A Case-Control study at MD Anderson Cancer Center. AACR special meeting (Lustgarten), 2004. e-Pub 2004.
67. Li D, Li Y, Jiao L, Hein DW, Doll M, Abbruzzese JL, Evans BD, Wolff RA, Lenzi R, Pisters PW, Bondy ML, Nooka A, Hassan MM. Polymorphisms of cytochrome P450 1A2 and N-acetyltransferase genes, cigarette smoking, and risk of pancreatic cancer. AACR special meeting (Lustgarten), 2004. e-Pub 2004.
68. Hassan MM, Nooka A, Stuff J, Day RS, Bondy ML, Abbruzzese JL, Evans DB, Wolff RA, Chou TH, Ho L, Xiong HQ, Lenzi R, Pisters PW, Li D. Environmental and Nutritional Factors and Pancreatic Cancer: A Case-Control Study in USA. AACR, special meeting (Lustgarten), 2004. e-Pub 2004.
69. Hassan MM, Nooka A, Brown TD, Thomas M, Abbruzzese J, Wolff R, Lozano R, Rashid A, Charnsangavej C, Ellis ML, Vauthey N, Patt YZ, Curley S. Prognostic Factors Analysis of 753 Hepatocellular Carcinoma: The impact of Hepatitis C Virus on the outcome of Hispanic patients. HCC meeting at the NIH, 2004. e-Pub 2004.
70. Jiao L, Hassan MM, Abbruzzese JL, Evans DB, Wolff RA, Lenzi R, Chou TH, Pisters PW, Nooka A, Li D. Genetic and epigenetic changes in plasma DNA of pancreatic cancer patients - association with tobacco smoking and implication for early diagnosis. AACR, 2004. e-Pub 2004.
71. Chang P, Hassan MM, Abbruzzese JL, Evans DB, Wolff RA, Lenzi R, Pisters PW, Nooka A, Li D. Background and H2O2-induced micronuclei in peripheral blood lymphocytes as a risk factor for pancreatic cancer. AACR, 2004. e-Pub 2004.
72. Hassan MM, Li Y, Nooka A, Thomas M, Brown TD, Curley S, Ellis ML, Vauthey N, Patt YZ, Li D. Polymorphisms of transforming growth factor-b1 (TFGFb1) gene and susceptibility to hepatocellular carcinoma. AACR, 2004. e-Pub 2004.
73. Li D, Stuff J, Day S, Abbruzzese JL, Evans DB, Wolff RA, Chou TH, Lenzi R, Pisters PW, Nooka A, Hassan MM. Dietary exposure to heterocyclic aromatic amines and risk of pancreatic cancer. AACR, 2004. e-Pub 2004.
74. Li Y, Ahmed M, Hassan MM, Abbruzzese JL, Nooka A, Wolff RA, Lenzi R, Evans DB, Pisters PW, Li D. Folate level, Methylenetetrahydrofolate Reductase Polymorphisms, and Risk of Pancreatic Cancer. AACR, 2004. e-Pub 2004.
75. Li D, Ahmed M, Abbruzzese J, Nooka A, Wolff RA, Lenzi R, Evans DB, Pisters PW, Hassan MM. Hlenetetrahydrofolate Reductase Polymorphisms and the Risk of Pancreatic Cancer. American Association for Cancer Research proceedings, 2003. e-Pub 2003.
76. Jiao L, Hassan MM, Firozi P, Abbruzzese JL, Evans D, Wolff R, Lenzi R, Pisters P, Nooka A, Li D. Tobacco smoking, Phase II drug metabolizing genes, and pancreatic cancer risk in Caucasians. American Association for Cancer Research proceedings, 2003. e-Pub 2003.
77. Hassan MM, Yao J. Improved survival outcome of carcinoid patients with distant diseases. American Society of Clinical Oncology Proceeding, 2003. e-Pub 2003.
78. Hassan MM, Zhang WQ, Nooka A, Patt YZ, Thomas M, Brown T, Li D. C262T Polymorphism of the catalase gene and susceptibility to hepatocellular carcinoma. American Association for Cancer Research proceedings, 2003. e-Pub 2003.
79. Li D, Hassan MM, Zhang WQ, Ahmed M, Thomas M, Brown T, Patt YZ. A Novel Glutathione Peroxidase Gene Codon 134 Polymorphism and Risk of Hepatocellular Carcinoma. American Association for Cancer Research proceedings, 2003. e-Pub 2003.
80. Lozano R, Ellis ML, Hassan MM, Nooka A, Brown DT, Patt YZ. Gemzar (G), Amfostine (A) and Cisplatin (P), (GAP) for Treatment of Hepatocellular Carcinoma Retrospective Analysis of Patients (pts.). American society of clinical Oncology Proceeding, 2003. e-Pub 2003.
81. Hassan MM, Ahmed M, Zhang WQ, Nooka A, Curley S, Brown DT, Ellis ML, Vauthey N, Patt YZ, Li D. C609T Polymorphism of the NAD(P)H: quinone oxidoreductase gene and susceptibility to hepatocellular carcinoma. American Association for Cancer Research proceedings, special meeting of molecular epidemiology, 2003. e-Pub 2003.
82. Chang P, Hassan MM, Abbruzzese JL, Evans D, Wolf R, Lenzi R, Pisters PW, Nooka A, Li D. Genetic susceptibility to carcinogen exposure and risk of pancreatic cancer. American Association for Cancer Research proceedings, 2003. e-Pub 2003.
83. Li D, Hassan MM, Zhang W, Zhu J, Swaim M, Schwartz RM, Ghalib R, Gudena V, Abbruzzese J, Patt YZ. Oxidative stress and 8-OH-dG in hepatocellular carcinoma and cirrhosis in relation to HCV and alcohol. American Association for Cancer Research:Abstract # 2841, 2002. e-Pub 2002.
84. Jiao L, Hassan MM, Gudena V, Connor HT, Abbruzese J, Li D. Susceptibility to pancreatic cancer and genetic polymorphisms of cytochrome P450 2E1 and O6-alkylguanine DNA alkyl transferase gene. American Association for Cancer Research proceedings:Abstract # 2849, 2002. e-Pub 2002.
85. Hassan MM, Zhang W, Zhu J, Patt YZ, Swaim M, Schwartz RM, Ghalib R, Gudena V, Abbruzzese J, Li D. Glutathione Peroxidase and GSH/GSS in hepatocellular carcinoma and cirrhosis in relation to HCV and alcohol. American Association for Cancer Research:Abstract # 4299, 2002. e-Pub 2002.
86. Lozano RD, Patt YZ, Ellis ML, Hassan MM, Chase J, Phan L, J-N V, Curley S, Abbruzzese J, Wolff R, Brown T. A Phase II Trial of a Hepatic Arterial Infusion (HAI) of Platinol (CDDP), Recombinant Human Interferon Alpha-2b (rIFNa), Adriamycin® (DOX), and 5-FU (PIAF) for the Treatment of Hepatocellular Carcinoma (HCC). American society of clinical Oncology Proceeding:Abstract # 666, 2001. e-Pub 2001.
87. Brown T, Patt YZ, Rowinsky EK, O'Reilly E, Hassan MM, Denis L, Kelvin L, Lozano R, Abbruzzese J, Wolff R, Lubicz S, De Jager RJ. A Phase II Study of Intravenous DX-8951f (Exatecan Mesylate) Administered Daily for Five Days Every Three Weeks to Patients with Hepatocellular Carcinoma. American society of clinical Oncology Proceeding:Abstract # 2345, 2001. e-Pub 2001.
88. Patt YZ, Lozano R, Hassan MM, Phan L, Ellis ML, J-N V, Curley S, Abbruzzese J, Wolff R, Brown T, Charnsangavej C. Continuous I.V. Infusion of 5-Fluorouracil (5-FU) and Subcutaneous (S.C.) Recombinant Interferon Alpha 2B (rIFNa2b) is an Active Regimen in Hepatocellular Carcinoma. American society of clinical Oncology Proceeding:Abstract # 671, 2001. e-Pub 2001.
89. Yaho J, Hassan MM. Increasing Incidence of Carcinoid in the United States. SEER 1992-1999. Special meeting of GI cancer, 2000. e-Pub 2000.
90. Chase J, Lozano RD, Hassan MM, Altamirano G, Garza J, Spencer J, Robinschon E, Heyd JM, Ellis ML, Curley S, Vauthey JN, Patt YZ. The Isomed Fixed Rate implantable Pump for the Delivery of Hepatic Arterial Chemotherapy and Intrathecal Pain Medication: a multi-center prospective accuracy and safety trial. American society of clinical Oncology Proceeding:Abstract # 1224, 2000. e-Pub 2000.
91. Lozano R, Patt YZ, Hassan MM, Brown T, Abbruzzese J, Curley, Vaughtey N. Oral Capecitabine (XelodaÔ) for the treatment of in Hepatobiliary Cancer (hepatocellular carcinoma, cholangiocarcinoma, and gallbladder cancer). American society of clinical Oncology Proceeding:Abstract # 1025, 2000. e-Pub 2000.
92. Patt YZ, Hassan MM, Lozano R, From A, Brown T, Abbruzzese J, Curley, Vaughtey N. Phase II study of Thalidomide for the treatment of hepatocellular carcinoma. American society of clinical Oncology Proceeding:Abstract # 1035, 2000. e-Pub 2000.
93. Patt YZ, Hassan MM, Lozano R, Hauque H, Wough K. Phase II Trial of Cisplatin (P), Intron a (I), Adriamycin (A), and 5 Fluoruracil (F) (PIAF) for biliary tree cancers (BTC). American Society of Clinical Oncology:1139, 1999. e-Pub 1999.
94. Hassan MM, Waugh K, Frome A, Lozano R, Hwang LY, Patt YZ. Interaction between heavy alcohol consumption and chronic hepatitis on the development of hepatocellular carcinoma. American Association for the Study of Liver Diseases, 1999. e-Pub 1999.
95. Hassan MM, Zaghloul A, Hwang LY, Chappell C, Soliman O, Beasley PR. Risk Factors of Hepatocellular Carcinoma in Egypt-Case-Control Study. Annal of Epidemiology 25:C135, 1997. e-Pub 1997.
96. Hassan MM, Patt YZ, Annegers F, Hwang LY. Hepatitis C Virus and Hepatocellular Carcinoma in USA. Am J Epi 345:S87, 1996. e-Pub 1996.

Book Chapters

1. MadulikaEluri, Hatia RI, Hassan Manal M. In: The association of family history of primary liver cancer with cholangiocarcinoma: USA case-control study. GI ASCO, 2021.
2. Hassan MM, Patt Y. Hepatocellular Cancer: Epidemiology and Molecular Epidemiology of Hepatocellular Cancer. In: The Principles and Practice of Gastrointestinal Oncology. Oxford University Press, 2000.
3. Patt YZ, Hassan MM. Hepatocellular Cancer: Clinical Aspects and Management of Hepatocellular Cancer. In: The Principles and Practice of Gastrointestinal Oncology. Oxford University Press, 2000.
4. Hassan MM, Yao J. Epidemiology of Neuroendocrine Tumors. In: Neuroendocrine Tumors. Springer Science + Business Media.
5. Hassan MM, Kaseb AO. Epidemiology and Pathogenesis of Hepatocellular Carcinoma. In: Hepatocellular Carcinoma: A Multi-Disciplinary Approach. Humana Press.

Letters to the Editor

1. Morris JS, Hassan M, Amin H, Kaseb A. Rejoinder to Hou, Liu and Hsu. Hepatology 73: 2612, 2021.
2. Morris JS, Hassan M, Amin H, Kaseb A. Rejoinder to Sun et al. letter:. Hepatology 73: 2614, 2021.
3. Hassan MM, Abdel-Wahab R, Li D, Kaseb AO. Reply to the relationship between obesity and hepatocellular carcinoma. Gastroenterology 149: 1643-4, 2015.
4. Li D, Hassan MM, Abbruzzese JL. Response to Dr. Goldstein and Colleagues' Comments 302: 1752-1753, 2009.
5. Hassan MM, Li D, Abbruzzese JL. Reply to "No association between hepatitis B and pancreatic cancer in a prospective study in Korea" by Amy Berrington de Gonzalez, Sun-Ha Jee, Eric A. Engels. J Clin Oncology 27: 648-9, 2009.
6. Hassan MM, Abbruzzese JL. Hypothyroidism and Hepatocellular Carcinoma: More Questions than Answers. Hepatology 50, 2009.
7. Kaseb AO, Morris JS, Hassan MM, Abbruzzese JL. Reply to A. Goya, et al. Future outlook of prognostic stratification of hepatocellular carcinoma. J Clin Oncol.